Salix Pharmaceuticals 10-Q/A 2 Mar 15 2014 Q3 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 05, 2014
Document And Entity Information [Abstract]
Document Type	10-Q/A
Amendment Flag	TRUE
Amendment Description	We are filing this Amendment No. 1 on Form 10-Q/A (“Form 10-Q/A”) to amend our Quarterly Report on Form 10 Q for the quarter ended September 30, 2014, originally filed with the Securities and Exchange Commission (the “SEC”) on November 7, 2014 (“Original Filing”) and restate our unaudited consolidated financial statements and related disclosures for the quarter ended September 30, 2014 and nine months ended September 30, 2014. This Form 10-Q/A also amends certain other items in the Original Filing, as listed in “Items Amended in the Form 10-Q/A” below as a result of the restatement. Details are discussed below and in Note 1A to the accompanying unaudited consolidated financial statements.
Document Period End Date	30-Sep-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Trading Symbol	SLXP
Entity Registrant Name	SALIX PHARMACEUTICALS LTD
Entity Central Index Key	1009356
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		63,723,282

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Jan. 02, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$422,578		$1,157,850	$817,725	$751,006
Restricted cash			750,000
Accounts receivable, net	507,428		133,581
Inventory	151,091		104,209
Deferred tax assets	222,106		85,788
Prepaid expenses and other current assets	182,313		51,241
Total current assets	1,485,516		2,282,669
Property and equipment, net	34,382		27,312
Goodwill	1,348,264	1,168,186	180,909
Product rights and intangibles, net	1,850,399		397,510
Other assets	98,188		37,551
Total assets	4,816,749		2,925,951
Current liabilities:
Accounts payable	49,926		32,632
Accrued liabilities	223,821		96,909
Income taxes payable			34,820
Reserve for product returns, rebates, chargebacks and patient-focused promotional programs	313,637		252,829
Current portion of convertible senior notes	911,263
Current portion of capital lease obligations	16		47
Total current liabilities	1,598,663		417,237
Long-term liabilities:
Convertible senior notes			882,050
Lease incentive obligation	9,233		8,610
Acquisition-related contingent consideration	165,037		87,300
Deferred tax liabilities	542,350		42,446
Other long-term liabilities	15,041		9,665
Total long-term liabilities	2,576,661		1,780,071
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, issuable in series, none outstanding
Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized, 63,718,571 and 62,937,966 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	64		63
Additional paid-in-capital	585,764		667,428
Accumulated other comprehensive income/(loss)	-278		1,721
Retained earnings/(accumulated deficit)	-67,836		59,431
Total stockholders' equity	517,714		728,643
Total liabilities, unamortized debt discount due on conversion of senior notes, and stockholders' equity	4,816,749		2,925,951
Term Loan B Facility [Member]
Current liabilities:
Current portion of Term Loan B credit facility	60,000
Current portion of acquisition-related contingent consideration	40,000
Long-term liabilities:
Term Loan B credit facility	1,095,000
6.60% Senior Notes Due 2021 [Member]
Long-term liabilities:
2021 senior notes	750,000		750,000
Convertible Senior Notes
Long-term liabilities:
Convertible senior notes	911,263		882,050
Unamortized debt discount due on conversion of senior notes	$123,711		$152,950

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	150,000,000
Common stock, shares issued	63,718,571	62,937,966
Common stock, shares outstanding	63,718,571	62,937,966

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:
Net product revenues	$341,547	$238,184	$1,120,066	$676,226
Costs and expenses:
Cost of products sold (excluding amortization of product rights and intangibles of $54042 and $11,189 for the three-month periods ended September 30, 2014 and 2013, and $161849 and $33,518 for the nine-month periods ended September 30, 2014 and 2013, respectively)	86,111	42,899	307,618	122,460
Amortization of product rights and intangible assets	54,042	11,189	161,849	33,518
Change in acquisition-related contingent consideration	76,549	2,400	90,737	7,000
Research and development (as revised)	36,678	29,180	103,476	85,891
Selling, general and administrative (as revised)	177,582	76,202	523,042	251,627
Total cost and expenses	430,962	161,870	1,186,722	500,496
Income (loss) from operations	-89,415	76,314	-66,656	175,730
Interest expense	-42,998	-15,497	-128,150	-46,285
Interest income and other income (expense)	-1,737	712	-1,451	1,348
Income (loss) before provision for income tax	-134,150	61,529	-196,257	130,793
Income tax (expense) benefit	41,042	-14,198	68,990	-40,021
Net income (loss)	-93,108	47,331	-127,267	90,772
Net income (loss) per share, basic	($1.46)	$0.77	($2)	$1.48
Net income (loss) per share, diluted	($1.46)	$0.71	($2)	$1.40
Shares used in computing net income (loss) per share, basic	63,687	61,763	63,482	61,416
Shares used in computing net income (loss) per share, diluted	63,687	66,829	63,482	65,031
Comprehensive income (loss)	($94,898)	$48,511	($129,265)	$91,427

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]
Amortization of product rights and intangible assets	$54,042	$11,189	$161,849	$33,518

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities
Net (loss) income	($127,267)	$90,772
Adjustments to reconcile net income (loss) to net cash (used) provided by operating activities:
Depreciation and amortization	168,665	38,965
Amortization of debt discount	29,239	27,933
Loss on disposal of property and equipment	555	113
Stock-based compensation expense	27,591	18,832
Change in acquisition-related contingent consideration	90,737	7,000
Changes in operating assets and liabilities:
Accounts receivable, inventory, prepaid expenses and other assets	-434,858	-168,361
Accounts payable, accrued and other liabilities	77,997	-3,744
Reserve for product returns, rebates, chargebacks and patient-focused promotional programs	19,916	63,849
Net cash (used) provided by operating activities	-147,425	75,359
Cash flows from investing activities
Business acquisition, net of cash and cash equivalents acquired	-2,472,203
Sale of short-term investments	44,867
Purchases of property and equipment	-13,376	-4,114
Net cash used in investing activities	-2,440,712	-4,114
Cash flows from financing activities
Debt issuance costs	-65,839
Extinguishment of 2015 convertible senior notes	-26	-12,500
Excess tax benefit from stock-based compensation	16,214	8,287
Payments related to net settlement of stock-based awards	-7,329	-4,037
Proceeds from issuance of common stock upon exercise of stock options	5,572	3,472
Net cash (used) provided by financing activities	1,853,592	-4,778
Effect of exchange rate changes on cash	-727	252
Net (decrease) increase in cash and cash equivalents	-735,272	66,719
Cash and cash equivalents at beginning of period	1,157,850	751,006
Cash and cash equivalents at end of period	422,578	817,725
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes	57,071	62,049
Cash paid for interest	78,326	15,781
6.60% Senior Notes Due 2021 [Member]
Cash flows from financing activities
Proceeds from senior notes	750,000
Term Loan B Facility [Member]
Cash flows from financing activities
Proceeds from Term Loan B credit facility	1,200,000
Principal payments on Term Loan B credit facility	($45,000)

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Organization and Basis of Presentation	1	Organization and Basis of Presentation
	Salix Pharmaceuticals, Ltd., a Delaware corporation referred to in this report as Salix or the Company, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract.
	These consolidated financial statements are stated in U.S. dollars and are prepared under accounting principles generally accepted in the United States. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in the consolidation.
	The accompanying consolidated financial statements include all adjustments that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows. These financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission. The results of operations for interim periods are not necessarily indicative of results to be expected for a full year or any future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC’s rules and regulations for interim reporting.

Restatement_of_Prior_Period_Fi

Restatement of Prior Period Financial Statements	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Restatement of Prior Period Financial Statements
	1A.	Restatement of Prior Period Financial Statements
	The Company has restated its previously reported unaudited consolidated financial statements for the quarter ended September 30, 2014 in order to correct certain previously reported amounts.
	As discussed in Part 1 of this Form 10-Q/A, the Audit Committee of the Board of Directors after discussion with management and the Company’s independent registered public accounting firm concluded that the Company’s previously issued unaudited consolidated financial statements for the fiscal quarters ended March 31, June 30, and September 30, 2014 and the disclosures and related communications for each of those periods, require correction of certain errors and should no longer be relied upon.
	The following tables present the effect of financial statement restatement adjustments on our previously reported unaudited consolidated financial statements at September 30, 2014 and for the three and nine months then ended:
	Consolidated Balance Sheet
	(U.S. dollars, in thousands, except per share amounts)
			September 30, 2014									December 31, 2013
			(Unaudited)
			As			Error			Restated			As		Error			Restated
			previously			Correction						previously		Correction
			reported									reported
	ASSETS
	Current assets:
	Cash and cash equivalents		$	422,578		$	—		$	422,578		$	1,157,850	$	—		$	1,157,850
	Restricted cash			—			—			—			750,000		—			750,000
	Accounts receivable, net			522,632			(15,204	)		507,428			147,933		(14,352	)		133,581
	Inventory			155,150			(4,059	)		151,091			104,395		(186	)		104,209
	Deferred tax assets			223,011			(905	)		222,106			86,693		(905	)		85,788
	Prepaid expenses and other current assets			168,054			14,259			182,313			51,241		—			51,241
	Total current assets			1,491,425			(5,909	)		1,485,516			2,298,112		(15,443	)		2,282,669
	Property and equipment, net			34,382			—			34,382			27,312		—			27,312
	Goodwill			1,310,060			38,204			1,348,264			180,909		—			180,909
	Product rights and intangibles, net			1,912,405			(62,006	)		1,850,399			397,510		—			397,510
	Other assets			98,188			—			98,188			37,551		—			37,551
	Total assets		$	4,846,460		$	(29,711	)	$	4,816,749		$	2,941,394	$	(15,443	)	$	2,925,951
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities:
	Accounts payable		$	45,258		$	4,668		$	49,926		$	32,632	$	—		$	32,632
	Accrued liabilities			220,642			3,179			223,821			97,661		(752	)		96,909
	Income taxes payable			—			—			—			43,354		(8,534	)		34,820
	Reserve for product returns, rebates, chargebacks and patient-focused promotional programs			316,293			(2,656	)		313,637			246,838		5,991			252,829
	Current portion of convertible senior notes			911,263			—			911,263			—		—			—
	Current portion of Term Loan B credit facility			60,000			—			60,000			—		—			—
	Current portion of acquisition-related contingent consideration			40,000			—			40,000			—		—			—
	Current portion of capital lease obligations			16			—			16			47		—			47
	Total current liabilities			1,593,472			5,191			1,598,663			420,532		(3,295	)		417,237
	Long-term liabilities:
	Convertible senior notes			—			—			—			882,050		—			882,050
	Lease incentive obligation			9,233			—			9,233			8,610		—			8,610
	Term Loan B credit facility			1,095,000			—			1,095,000			—		—			—
	2021 senior notes			750,000			—			750,000			750,000		—			750,000
	Acquisition-related contingent consideration			165,037			—			165,037			87,300		—			87,300
	Deferred tax liabilities			567,014			(24,664	)		542,350			42,371		75			42,446
	Other long-term liabilities			15,041			—			15,041			9,665		—			9,665
	Total long-term liabilities			2,601,325			(24,664	)		2,576,661			1,779,996		75			1,780,071
	Unamortized debt discount due on conversion of senior notes			123,711			—			123,711			—		—			—
	Stockholders’ equity:
	Preferred stock, $0.001 par value; 5,000,000 shares authorized, issuable in series, none outstanding			—			—			—			—		—			—
	Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized, 63,718,571 and 62,937,966 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively			64			—			64			63		—			63
	Additional paid-in-capital			585,701			63			585,764			667,428		—			667,428
	Accumulated other comprehensive income/(loss)			(278	)		—			(278	)		1,721		—			1,721
	Retained earnings/(accumulated deficit)			(57,535	)		(10,301	)		(67,836	)		71,654		(12,223	)		59,431
	Total stockholders’ equity
				527,952			(10,238	)		517,714			740,866		(12,223	)		728,643
	Total liabilities and stockholders’ equity
			$	4,846,460		$	(29,711	)	$	4,816,749		$	2,941,394	$	(15,443	)	$	2,925,951
	Consolidated Statement of Comprehensive Income (Loss)
	(U.S. dollars, in thousands, except per share data)
			Nine Months Ended September 30, 2014
			(unaudited)
			As			Error			As Restated
			previously			Correction
			reported
Revenues:
Net product revenues		$	1,121,093		$	(1,027	)	$	1,120,066
Costs and expenses:
Cost of products sold (excluding amortization of product rights and intangibles of $161,849 for the nine-month period ended September 30, 2014.)			306,189			1,429			307,618
Amortization of product rights and intangible assets			164,843			(2,994	)		161,849
Change in acquisition-related contingent consideration			90,737			—			90,737
Research and development			142,826			(39,350	)		103,476
Selling, general and administrative			485,764			37,278			523,042
Total cost and expenses			1,190,359			(3,637	)		1,186,722
Income (loss) from operations			(69,266	)		2,610			(66,656	)
Interest expense			(128,525	)		375			(128,150	)
Interest income and other income (expense)			(1,451	)		—			(1,451	)
Income (loss) before provision for income tax			(199,242	)		2,985			(196,257	)
Income tax (expense) benefit			70,053			(1,063	)		68,990
Net income (loss)		$	(129,189	)	$	1,922		$	(127,267	)
Net income (loss) per share, basic		$	(2.04	)	$	0.03		$	(2.00	)
Net income (loss) per share, diluted		$	(2.04	)	$	0.03		$	(2.00	)
Shares used in computing net income (loss) per share, basic			63,482			—			63,482
Shares used in computing net income (loss) per share, diluted			63,482			—			63,482
Comprehensive income (loss)		$	(131,187	)	$	1,922		$	(129,265	)
		Three Months Ended September 30, 2014
		(unaudited)
		As			Error			As Restated
		previously			Correction
		reported
Revenues:
Net product revenues		$	354,719		$	(13,172	)	$	341,547
Costs and expenses:
Cost of products sold (excluding amortization of product rights and intangibles of $54,042 the three-month period ended September 30, 2014.)			86,298			(187	)		86,111
Amortization of product rights and intangible assets			55,040			(998	)		54,042
Change in acquisition-related contingent consideration			76,549			—			76,549
Research and development			50,837			(14,159	)		36,678
Selling, general and administrative			165,622			11,960			177,582
Total cost and expenses			434,346			(3,384	)		430,962
Income (loss) from operations			(79,627	)		(9,788	)		(89,415	)
Interest expense			(43,623	)		625			(42,998	)
Interest income and other income (expense)			(1,737	)		—			(1,737	)
Income (loss) before provision for income tax			(124,987	)		(9,163	)		(134,150	)
Income tax (expense) benefit			36,392			4,650			41,042
Net income (loss)		$	(88,595	)	$	(4,513	)	$	(93,108	)
Net income (loss) per share, basic		$	(1.39	)	$	(0.07	)	$	(1.46	)
Net income (loss) per share, diluted		$	(1.39	)	$	(0.07	)	$	(1.46	)
Shares used in computing net income (loss) per share, basic			63,687			—			63,687
Shares used in computing net income (loss) per share, diluted			63,687			—			63,687
Comprehensive income (loss)		$	(90,385	)	$	(4,513	)	$	(94,898	)
Consolidated Statement of Cash Flows
(U.S. dollars, in thousands, except per share amounts)
		Nine Months Ended September 30, 2014
		(unaudited)
		As previously			Error			As Restated
		reported			Correction
Cash Flows from Operating Activities
Net income (loss)		$	(129,189	)	$	1,922		$	(127,267	)
Adjustments to reconcile net income (loss) to net cash (used) provided by operating activities:						—			—
Depreciation and amortization			171,659			(2,994	)		168,665
Amortization of debt discount			29,239			—			29,239
Loss on disposal of property and equipment			555			—			555
Stock-based compensation expense			27,591			—			27,591
Change in acquisition-related contingent consideration			90,737			—			90,737
Changes in operating assets and liabilities:
Accounts receivable, inventory, prepaid expenses and other assets			(427,380	)		(7,478	)		(434,858	)
Accounts payable, accrued and other liabilities			60,863			17,134			77,997
Reserve for product returns, rebates, chargebacks and patient-focused promotional programs			28,563			(8,647	)		19,916
Net cash (used) provided by operating activities			(147,362	)		(63	)		(147,425	)
Cash Flows from Investing Activities
Business acquisitions, net of cash and cash equivalents acquired			(2,472,203	)		—			(2,472,203	)
Sale of short-term investments			44,867			—			44,867
Purchases of property and equipment			(13,376	)		—			(13,376	)
Net cash used by investing activities			(2,440,712	)		—			(2,440,712	)
Cash Flows from Financing Activities
Proceeds from senior notes			750,000			—			750,000
Proceeds from Term Loan B credit facility			1,200,000			—			1,200,000
Debt issuance costs			(65,839	)		—			(65,839	)
Principal payments on Term Loan B credit facility			(45,000	)		—			(45,000	)
Extinguishment of 2015 convertible senior notes			(26	)		—			(26	)
Excess tax benefit from stock-based compensation			16,151			63			16,214
Payments related to net settlement of stock-based awards			(7,329	)		—			(7,329	)
Proceeds from issuance of common stock upon exercise of stock options			5,572			—			5,572
Net cash provided (used) by financing activities			1,853,529			63			1,853,592
Effect of exchange rate changes on cash			(727	)		—			(727	)
Net (decrease) increase in cash and cash equivalents			(735,272	)		—			(735,272	)
Cash and cash equivalents at beginning of period			1,157,850			—			1,157,850
Cash and cash equivalents at end of period		$	422,578		$	—		$	422,578
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes		$	57,071		$	—		$	57,071
Cash paid for interest		$	78,326		$	—		$	78,326

Business_Combination

Business Combination

9 Months Ended

Sep. 30, 2014

Business Combinations [Abstract]

Business Combination

2

Business Combination

On January 2, 2014, the Company completed a tender offer for all outstanding shares of common stock, par value $0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value $0.0001 per share, of Santarus, Inc., or Santarus, at a purchase price of $32.00 per share. Following the tender offer, Salix completed the acquisition of Santarus through a merger under Section 251(h) of the Delaware General Corporation Law. The aggregate consideration for the acquisition of Santarus was approximately $2.7 billion. The Company financed the acquisition and transaction costs through a combination of (i) the term loan facility in the principal amount of $1.2 billion, or the Term Loan B Credit Facility, (ii) the net proceeds from the Company’s issuance of $750.0 million of 6.00% senior notes due 2021, or the 2021 Notes and (iii) cash on hand of approximately $848.1 million.

Among the reasons the Company acquired Santarus and the factors that contributed to the recognition of goodwill are the Company’s belief that the transaction will strengthen the Company’s position as a leader in the gastroenterology pharmaceuticals space in the United States, offering a complementary portfolio of well-known and profitable drugs, and will allow the Company to expand the size and reach of its sales force. The transaction was accounted for as a business combination under the acquisition method of accounting. Accordingly, the tangible assets and identifiable intangible assets acquired and liabilities assumed were recorded at fair value as of the date of acquisition, with the remaining purchase price recorded as goodwill.

The Company is amending its purchase price allocation as of the acquisition date to reflect certain measurement period adjustments through the fourth quarter 2014 as further described below.

The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition:

($ in thousands and unaudited)

January 2, 2014

(Restated)

Total consideration

$

2,671,212

Tangible assets acquired and liabilities assumed:

Cash and cash equivalents

171,259

Restricted cash

750

Investments

44,867

Account receivables, net

50,634

Inventory

49,498

Current deferred tax assets

146,670

Prepaid expenses and other current assets

7,353

Property and equipment, net

1,064

Other assets acquired

731

Accounts payable

(11,142

)

Accrued expenses

(20,203

)

Reserve for product returns, rebates and chargebacks

(40,892

)

Long-term deferred tax liability

(509,801

)

Other long-term liabilities

(3,762

)

Total tangible assets acquired and liabilities assumed

(112,974

)

Intangible assets acquired:

Currently marketed products (CMPs)

1,489,000

In-process research & development products (IPR&D)

83,000

Contractual agreements

44,000

Total intangible assets acquired

1,616,000

Total tangible and intangible assets acquired and liabilities assumed

1,503,026

Goodwill

$

1,168,186

Goodwill was calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. Consideration transferred as of the acquisition-date included $27 million of acquisition-related contingent consideration. The Company reviews the fair value of contingent consideration quarterly or whenever events or changes in circumstances occur that indicate there has been a change in the fair value as described in Note 8. The goodwill is not expected to be deductible for income tax purposes. Goodwill was recorded as an indefinite-lived asset and is not being amortized but is tested for impairment on an annual basis or when indications of impairment exist. The measurement period adjustments relate to tax adjustments associated with the acquisition of Santarus.

Inventories

The fair value of inventories acquired included a step-up in the value of inventories of $37.3 million. In the three-month and nine-month periods ended September 30, 2014, the Company recognized $2.5 million and $37.2 million of this step-up in value as a component of cost of sales, respectively, as the inventory acquired on January 2, 2014 was sold to the Company’s customers.

IPR&D and Intangible Assets

IPR&D intangible assets represent the value assigned to acquired R&D projects that, as of the acquisition date, had not established technological feasibility and had no alternative future use. The IPR&D intangible assets are capitalized and accounted for as indefinite-lived intangible assets and will be subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project and launch of the product, the Company will make a separate determination of the estimated useful life of the IPR&D intangible asset and the related amortization will be recorded as an expense over the estimated useful life. Intangible assets represent CMPs and as of the acquisition-date had an estimated weighted average useful life of 15.4 years.

The estimated fair value of the IPR&D and identifiable intangible assets was determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset is expected to generate over its remaining useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset or product (including net revenues, cost of sales, R&D costs, selling and marketing costs and working capital/asset contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. The discount rates used to arrive at the present value at the acquisition date of CMPs ranged from 9.0% to 9.5% and for IPR&D ranged from 10.0% to 11.0%, to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will remain unchanged. For these and other reasons, actual results may vary significantly from estimated results.

See table in Pro Forma Financial Information (unaudited) below for the summarized amounts recognized and the weighted average useful lives of intangible assets:

Deferred Tax

The deferred tax assets of $146.7 million are primarily related to acquired tax attributes and other reserves and accruals. The deferred tax liability of $509.8 million is primarily related to the temporary differences associated with acquired intangible assets, which are not deductible for tax purposes.

Acquiree Results

The operating results of Santarus for the three-month period ended September 30, 2014 and the period from January 2, 2014 to September 30, 2014, including net revenues of $134.6 million and $565.6 million and operating income of $16.3 million and $138.0 million, have been included in the Company’s consolidated financial statements as of and for the three-month and nine month periods ended September 30, 2014, respectively.

Acquisition-Related Expenses

The Company incurred a total of $126.8 million in transaction costs in connection with the acquisition. Of these transaction costs, $65.5 million was included in selling, general and administrative expenses for the nine-month period ended September 30, 2014 and $61.3 million was capitalized as debt issuance costs and is being amortized as incremental interest expense.

Pro Forma Financial Information (unaudited)

The following unaudited pro forma information presents certain results of operations of the combined companies for the periods indicated as if the acquisition had been consummated on January 1, 2013, combining the respective historical results of Salix and Santarus for the three-month and nine-month periods ended September 30, 2013. Santarus’ results of operations have been included in Salix’s financial statements for periods subsequent to the completion of the acquisition on January 2, 2014. The pro forma results include amortization associated with the acquired intangible assets and interest on funds used for the acquisition. The unaudited pro forma financial information presented below does not reflect the impact of any actual or anticipated synergies expected to result from the acquisition. Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date.

($ in thousands)

Three Month

Nine Month

Period Ended

Period Ended

September 30,

September 30,

2013

2013

Revenue

$

336,978

$

943,822

Net income

36,425

49,675

Basic income per share

0.59

0.81

Diluted income per share

0.55

0.76

The unaudited pro forma data reflect the application of the following adjustments:

•

Non-recurring transaction expenses of $65.5 million in the nine-month period ended September 30, 2013 reflected as if they were incurred in the corresponding 2013 period, due to the pro forma assumption of January 1, 2013 as the date of the acquisition consummation.

•

Incremental amortization expense of $41.1 million and $123.5 million for the three-month and nine-month periods ended September 30, 2013, respectively, resulting from the fair value adjustment for purchase accounting for the acquisition of Santarus.

($ in thousands)

Weighted

Estimated

Amortization

Amortization

Average

Fair Value

Expense for the

Expense for the

Useful Life

As of

Three Month Period

Nine Month Period

(years)

Acquisition

Ended

Ended

Date

September 30, 2013

September 30,

2013

IPR&D

N/A

83,000

—

—

Product rights on CMPs

15.4

1,489,000

41,657

124,996

Licensing agreements

10

44,000

1,100

3,300

Total pro forma amortization expense

42,757

128,296

Less: historical amortization expense

(1,627

)

(4,752

)

Net adjustment

41,130

123,544

Incremental interest expense of $26.5 million and $79.3 million for the three and nine-month periods ended September 30, 2013, respectively, related to the Company’s debt structure after the acquisition of Santarus, comprised of $750 million of 2021 Notes and $1.2 billion in principal amount of borrowings under the Term Loan B Facility as if the debt had been issued on January 1, 2013.

($ in thousands)

Three Month

Nine Month

Period Ended

Period Ended

September 30,

September 30,

2013

2013

Interest on Term Loan B Facility of $1.2 billion and $750 million of 2021 Notes at an assumed weighted average cash interest rate of approximately 4.92%

24,000

72,000

Amortization of debt issue costs and original issue discount

2,451

7,265

Total adjustment

26,451

79,265

•

The income tax effect of the pro forma adjustments using a combined federal and state statutory income tax rate of 39.0%. The effective tax rate of the combined company could be significantly different (either higher or lower) depending on post-acquisition integration activities, cash needs and the geographical mix of income.

Revenue_Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]
Revenue Recognition	3	Revenue Recognition
	The Company recognizes revenue when it is realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (a) persuasive evidence of an arrangement exists; (b) delivery has occurred or services have been rendered; (c) the Company’s price to the buyer is fixed or determinable; and (d) collectability is reasonably assured.
	The Company recognizes revenues for product sales at the time title and risk of loss are transferred to the customer, which is generally at the time products are shipped (unless products are shipped under FOB Destination shipping terms, in which case risk of loss is transferred to the customer upon delivery). The Company recognizes revenue from sales transactions where the buyer has the right to return the product at the time of sale only if (1) the Company’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the Company, or the buyer is obligated to pay the Company and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from any provided by the Company, (5) the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated. The Company’s net product revenue represents the Company’s total revenues less allowances for customer credits, including wholesaler discounts, estimated rebates, chargebacks, promotional programs and product returns.
	The Company establishes allowances for estimated rebates, chargebacks and product returns based on numerous qualitative and quantitative factors, including:
		•	the number of and specific contractual terms of agreements with customers;
		•	estimated levels of inventory in the distribution channel;
		•	historical rebates, chargebacks and returns of products;
		•	direct communication with customers;
		•	anticipated introduction of competitive products or generics;
		•	anticipated pricing strategy changes by the Company and/or its competitors;
		•	analysis of prescription data gathered by a third-party prescription data provider;
		•	the impact of changes in state and federal regulations; and
		•	the estimated remaining shelf life of products.
	In its analyses, the Company uses prescription data purchased from a third-party data provider to develop estimates of historical inventory channel pull-through. The Company utilizes an internal analysis to compare historical net product shipments to estimated historical prescriptions written. Based on that analysis, management develops an estimate of the quantity of product in the channel which may be subject to various rebate, chargeback and product return exposures. To estimate months of ending inventory in the distribution channel the Company divides estimated ending inventory in the distribution channel by the Company’s estimate of the succeeding quarter’s demand, not taking into account any future anticipated demand growth beyond the succeeding quarter. At least quarterly for each product line, the Company prepares an internal estimate of ending inventory units in the distribution channel by adding estimated inventory in the channel at the beginning of the period, plus net product shipments for the period, less estimated prescriptions written for the period. To estimate months of ending inventory in the distribution channel the Company divides estimated ending inventory in the distribution channel by the Company’s estimate of the succeeding quarter’s demand, not taking into account any future anticipated demand growth beyond the succeeding quarter. Based on that analysis, the Company develops an estimate of the quantity of product in the channel that might be subject to various rebate, chargeback and product return exposures. This is done for each product line by applying a rate of historical activity for rebates, chargebacks and product returns, adjusted for relevant quantitative and qualitative factors discussed above, to the potential exposed product estimated to be in the distribution channel. The Company regularly adjusts internal forecasts that are utilized to calculate the estimated number of months in the channel based on input from members of the Company’s sales, marketing and operations groups. The adjusted forecasts take into account numerous factors including, but not limited to, new product introductions, direct communication with customers and potential product expiry issues. Adjustments to estimates are recorded in the period when significant events or changes in trends are identified.
	The Company offers discounts to the Company’s wholesalers and other customers. These discounts are calculated as a percentage of the current published list price and are treated as off-invoice allowances. Accordingly, the discounts are recorded as a reduction of revenue in the period that the discounts are offered. In addition to these discounts, at the time that the Company implements a price increase, it generally offers its existing customer base an opportunity to purchase a limited quantity of product at the previous list price. Shipments resulting from these offers generally are not in excess of ordinary levels; therefore, the Company recognizes the related revenue upon shipment and includes the shipments in estimating various product related allowances. In the event the Company determines that these shipments represent purchases of inventory in excess of ordinary levels for a given wholesaler, the potential impact on product returns exposure would be specifically evaluated and reflected as a reduction in revenue at the time of such shipments.
	Allowances for estimated rebates, chargebacks and promotional patient-focused programs were $257.4 million and $184.6 million as of September 30, 2014 and December 31, 2013, respectively. These allowances reflect an estimate of the Company’s liability for items such as rebates due to various governmental organizations under the Medicare/Medicaid regulations, rebates due to managed care organizations under specific contracts and chargebacks due to various organizations purchasing products through federal contracts and/or group purchasing agreements. The Company estimates its liability for rebates, chargebacks and patient-focused promotional programs at each reporting period based on a methodology of applying quantitative and qualitative assumptions. Due to the subjectivity of the Company’s accrual estimates for rebates and chargebacks, the Company prepares various sensitivity analyses to ensure the Company’s final estimate is within a reasonable range as well as reviews prior period activity to ensure that the Company’s methodology continues to be appropriate.
	Allowances for product returns were $56.2 million and $68.2 million as of September 30, 2014 and December 31, 2013, respectively. These allowances reflect an estimate of the Company’s liability for products that may be returned by the original purchaser in accordance with the Company’s stated return policy. The Company estimates its liability for product returns at each reporting period based on historical return rates, estimated inventory in the channel and the other factors discussed above. Due to the subjectivity of the Company’s accrual estimates for product returns, the Company prepares various sensitivity analyses and also reviews prior period activity to ensure that the Company’s methodology is still reasonable.
	The Company’s provision for rebates, chargebacks, patient-focused promotional programs and product returns as a percentage of gross product revenue in the three-month periods ended September 30, 2014 and 2013 was 24.3% and 23.7%, respectively, for rebates, chargebacks and patient-focused promotional programs and was (2.8)% and 1.8%, respectively, for product returns. The Company’s provision for rebates, chargebacks, patient-focused promotional programs and product returns as a percentage of gross product revenue in the nine-month periods ended September 30, 2014 and 2013 was 19.6% and 21.9%, respectively, for rebates, chargebacks and patient-focused promotional programs and was 0.4% and 2.1%, respectively, for product returns.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments	4	Commitments
	Purchase Order Commitments
	At September 30, 2014, the Company had binding purchase order commitments for inventory purchases aggregating approximately $181.1 million.
	Potential Milestone Payments
	The Company has entered into collaborative agreements with licensors, licensees and others. Pursuant to the terms of these collaborative agreements, the Company is obligated to make one or more payments upon the occurrence of certain milestones. The following is a summary of the material payments that the Company might be required to make under its collaborative agreements if certain milestones are satisfied.
	Amended and Restated License Agreement with Alfa Wassermann S.p.A.—In August 2012, the Company amended its 1996 License Agreement, or the 1996 Agreement, with Alfa Wassermann, S.p.A., or Alfa, to develop and commercialize rifaximin. The restated agreement provides the Company with an exclusive license to develop and commercialize rifaximin products for Crohn’s disease in the United States and Canada and a non-exclusive license to develop such products worldwide. The Company paid Alfa a non-refundable upfront fee of $10.0 million in August 2012, and is obligated to make a $25.0 million milestone payment upon receipt of marketing authorization in the United States for a delayed release formulation rifaximin product for Crohn’s disease, and additional milestone payments of up to $200.0 million based on net sales of delayed release formulation rifaximin products for Crohn’s disease. No milestone payment had been earned or made as of September 30, 2014.
	License Agreement with Dr. Falk Pharma GmbH for budesonide—In March 2008, the Company entered into a license agreement with Dr. Falk Pharma GmbH, or Dr. Falk Pharma, that provides the Company with an exclusive license to develop and commercialize Dr. Falk Pharma’s budesonide rectal foam product in the United States. This product has patent protection in the United States until 2015. Pursuant to the license agreement the Company is obligated to make an upfront payment and regulatory milestone payments that could total up to $9.5 million to Dr. Falk Pharma, with the majority contingent upon U.S. regulatory approval of a foam product. As of September 30, 2014, the Company had paid $2.5 million of these milestone payments. On October 7, 2014, the FDA granted Salix approval for Uceris budesonide rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis; therefore, the $7.0 million milestone payment was earned and is expected to be paid in the fourth quarter of 2014.
	Development, Commercialization and License Agreement with Lupin Ltd.—In September 2009, the Company entered into a Development, Commercialization and License Agreement with Lupin Ltd, or Lupin, for Lupin’s proprietary drug delivery technology for rifaximin. The Company made an upfront payment of $5.0 million to Lupin upon execution of this agreement.
	In March 2011, the Company entered into an amendment and restatement of its Development, Commercialization and License Agreement with Lupin, and further amended it in February 2013, as so amended, the Amended License Agreement. The Amended License Agreement replaces in its entirety the September 2009 agreement. This agreement provides that the Company is obligated to pay Lupin an additional upfront payment of $10.0 million, milestone payments that could total up to $53.0 million over the term of the agreement and royalties in connection with the commercialization of relevant products. The milestone payments are contingent upon achievement of certain clinical and regulatory milestones. During the portion of the term of the Amended License Agreement ending September 30, 2019, the Company must pay Lupin a minimum quarterly payment unless specified payments by the Company to Lupin during that quarter exceed that amount. The Company is permitted to charge against such minimum quarterly payments as it makes them in respect of quarters beginning on or after January 1, 2012, the purchase price for certain rifaximin to be supplied to it by Lupin pursuant to a Rifaximin Manufacturing and Supply Agreement into which the Company and Lupin entered in September 2009 and subsequently amended. In the event the Company should exercise its right to terminate the Amended License Agreement for convenience, it must pay Lupin as an early termination fee a specified portion of the minimum quarterly payments payable by it to Lupin through September 30, 2019, that have not been paid or otherwise satisfied as of the date of termination. As of September 30, 2014, the Company had paid the additional $10.0 million upfront payment.
	License Agreement with Napo Pharmaceuticals, Inc.—In December 2008, the Company entered into a collaboration agreement with Napo Pharmaceuticals, Inc., or Napo. Pursuant to the agreement, the Company has an exclusive, royalty-bearing license to crofelemer (trade name Fulyzaq) for all human uses in North America and much of Europe and for all human uses other than the treatment of HIV-associated diarrhea, pediatric diarrhea and acute infectious diarrhea in other regions. The Company also has a non-exclusive, worldwide, royalty-bearing license to use Napo-controlled trademarks associated with crofelemer. The Company has made an initial payment of $5.0 million to Napo and agreed to make up to $50.0 million in milestone payments to Napo contingent on regulatory approvals and up to $250.0 million in milestone payments contingent on reaching certain sales thresholds. The Company is responsible for the development costs of crofelemer, but costs exceeding $12.0 million for development of crofelemer used for the HIV-associated diarrhea indication have been credited against regulatory milestones and thereafter against sales milestones. On December 31, 2012, the Food and Drug Administration, or FDA, granted marketing approval for this product, under the trade name Fulyzaq and as of that date, development costs exceeded $12.0 million by more than the amount of the milestone due upon FDA marketing approval; therefore there was no payment due to Napo at that time. As of September 30, 2014, none of the sales thresholds that would potentially trigger other milestone payments had been satisfied.
	License and Supply Agreement with Norgine B.V.—In December 2005, the Company entered into a license and supply agreement with Norgine B.V., or Norgine, for the rights to sell NRL944, a bowel cleansing product the Company now markets in the United States under the trade name MoviPrep. Pursuant to the terms of this agreement, the Company is obligated to make upfront and milestone payments to Norgine that could total up to $37.0 million over the term of the agreement. As of September 30, 2014, the Company had paid Norgine $27.0 million in milestone payments. The remaining milestone payments are contingent upon reaching sales thresholds that have not been satisfied.
	License Agreement with Progenics Pharmaceuticals, Inc.—In February 2011, the Company acquired an exclusive license to develop and commercialize products containing methylnaltrexone bromide, or the MNTX Compound, marketed under the name Relistor®, from Progenics Pharmaceuticals, Inc., or Progenics. The license is now worldwide, following Progenics’ termination of Ono Pharmaceutical Co. Ltd.’s rights to Japan. The Company paid Progenics an up-front license fee of $60.0 million. In addition, the Company is obligated to pay development milestone payments of up to $90.0 million contingent upon achieving specified regulatory approvals and commercialization milestone payments of up to $200.0 million contingent upon achieving specified targets for net sales over the term of the agreement. No milestone payments had been earned or made as of September 30, 2014. The Company made a $40.0 million milestone payment to Progenics in October 2014 upon FDA approval of Relistor (methylnaltrexone bromide) Subcutaneous Injection, 12 mg/0.6ml, for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain.
	License Agreements and Stock Purchase Agreement with Q-Med AB—In connection with the Company’s acquisition of Oceana Therapeutics, Inc., or Oceana, in December 2011, the Company acquired two license agreements with Q-Med AB, or Q-Med, which provide it the worldwide right to commercialize Deflux and Solesta. Under a stock purchase agreement with Q-Med that was assumed in connection with the Oceana transaction, the Company is obligated to pay commercialization milestone payments of up to $45.0 million contingent upon achieving specified targets for net sales of Solesta over the term of the agreement. No milestone payments had been earned or made as of September 30, 2014.
	License Agreement with Cosmo Technologies Limited—In December 2008, Santarus entered into a strategic collaboration with Cosmo Technologies Limited, or Cosmo Tech, including a license agreement, stock issuance agreement and registration rights agreement, under which Santarus was granted exclusive rights to develop and commercialize Uceris in the United States. In November 2013, Santarus, Cosmo Tech, and Salix amended the original license agreement in connection with Salix’s acquisition of Santarus, and Cosmo Tech consented to the development, promotion and marketing in the United States by Salix, Santarus and any of their subsidiaries of budesonide products, provided that Salix, Santarus and their subsidiaries would be prohibited from developing, promoting or marketing an oral formulation budesonide product other than Uceris for human use. In addition, the parties agreed to the termination of the stock issuance and registration rights agreements. To date, Santarus has made upfront licensing and milestone payments to Cosmo Tech under the license agreement, as amended, consisting of $9.5 million in cash. Certain milestone payments under the original license agreement were paid in Santarus stock. In the future, Santarus may be required to pay Cosmo Tech in cash commercial milestones for Uceris of up to $22.5 million. As of September 30, 2014 $22.5 million of the milestone payments had been earned.
	License Agreement with University of Missouri—In January 2001, Santarus entered into an exclusive, worldwide license agreement with the University of Missouri for patents and pending patent applications relating to specific formulations of proton pump inhibitors with antacids and other buffering agents and methods of using these formulations. Under the terms of the license agreement, Santarus has paid to the University of Missouri $8.5 million in upfront licensing and milestone payments as of September 30, 2014. Santarus remains obligated to make additional commercialization milestone payments to the University of Missouri of up to $83.8 million, the next of which is a one-time $7.5 million milestone payment upon initial achievement of $250.0 million in annual calendar year net product sales of Zegerid.
	License Agreement and Supply Agreement with Pharming Group NV—In September 2010, Santarus entered into a license agreement and a supply agreement with Pharming Group NV, or Pharming, under which Santarus was granted certain non-exclusive rights to develop and manufacture, and certain exclusive rights to commercialize Ruconest in the U.S., Canada and Mexico for the treatment of hereditary angioedema, or HAE, and other future indications. In partial consideration of the licenses granted under the license agreement, Santarus paid Pharming a $15 million upfront fee. In addition, in November 2012, Santarus paid Pharming a $10 million milestone following successful achievement of the primary endpoint of the phase 3 clinical study. Santarus paid a $5 million milestone to Pharming in July 2013 upon FDA acceptance for review of a BLA, for Ruconest. Santarus may also be required to pay Pharming additional success-based regulatory and commercial milestones totaling up to an aggregate of $25 million, including a $20 million milestone upon the earlier of first commercial sale of Ruconest in the U.S. or 90 days following receipt of both FDA approval and launch supplies from Pharming, and commercialization milestone payments of up to $45.0 million contingent upon achieving specified targets for net sales of Ruconest over the term of the agreement. On July 16, 2014, the FDA approved Ruconest for the treatment of acute angioedema attacks in adult and adolescent patients with HAE; therefore the $20 million milestone payment is expected to be earned in the fourth quarter of 2014.
	License Agreement and Supply Agreement with Biogen Idec MA—In September 2010, in connection with Santarus’ acquisition of Covella Pharmaceuticals, Inc., or Covella, Santarus acquired the exclusive worldwide rights to SAN-300, a product candidate and humanized anti-VLA-1 monoclonal antibody, or mAb, for the treatment of certain inflammatory and autoimmune diseases. Under the terms of an amended and restated license agreement entered into among Santarus, Covella and Biogen Idec MA, or Biogen, at the time of the acquisition, Biogen has granted to Santarus an exclusive, worldwide license to patents and certain know-how and other intellectual property owned and controlled by Biogen relating to SAN-300 and the anti-VLA-1 mAb development program. The amounts of the clinical and regulatory milestone payments that Santarus will be obligated to pay to Biogen vary depending on the type of product, the number of indications, and other specifically negotiated milestones. If SAN-300 is the first to achieve all applicable milestones for three indications, Santarus will be required to pay to Biogen maximum aggregate clinical and regulatory milestone payments of $97.2 million. The maximum aggregate commercialization milestone payments to Biogen total $105.5 million for SAN-300, assuming cumulative net sales of at least $5.0 billion of such product, and total $60.25 million for products containing certain other compositions as described in the amended and restated license agreement, assuming cumulative net sales of at least $5.0 billion of such products. No milestone payments had been earned as of September 30, 2014.
	License Agreement with RedHill Biopharma Ltd.—In February 2014, the Company entered into an agreement with RedHill Biopharma Ltd., or RedHill, whereby it licensed the worldwide exclusive rights to RedHill’s RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments. Concurrently the Company licensed additional related intellectual property from four individuals. In connection with these agreements, the Company made upfront payments of $11.5 million and is obligated to make development milestone payments of up to $12.5 million contingent upon achieving specified regulatory approvals and commercialization milestone payments of up to $15.0 million contingent upon achieving specified targets for net sales over the term of the agreement. No milestone payments had been earned as of September 30, 2014.
	License Agreement with Cipla, Ltd.—In October 2009, the Company entered into an exclusive royalty bearing license agreement with Cipla, Ltd., or Cipla, whereby it licensed certain rifaximin rights from Cipla in the U.S., Canada and Mexico. In connection with this agreement, the Company made an upfront payment of $2.0 million and is obligated to make milestone payments of up to $6.0 million contingent upon achieving specified patent approvals and listings. No milestone payments had been earned as of September 30, 2014.
	In September 2014, the Company entered into an amendment to the exclusive license agreement with Cipla to expand the territories to include Australia, all member states of the European Union, Japan, New Zealand, South Korea, as well as Canada, Mexico and the U.S. In connection with this agreement, the Company made an upfront payment of $1.0 million.
	In September 2014, the Company entered into an exclusive royalty bearing license agreement with Cipla whereby it licensed rights from Cipla to certain enumerated patents and patent applications in the “Rifaximin complexes” patent family controlled by Cipla on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa. In connection with this agreement, the Company made an upfront payment of $9.0 million and is obligated to make milestone payments of up to $20.0 million contingent upon achieving specified patent approvals and listings. No milestone payments had been earned as of September 30, 2014.

Financial_Instruments_Recurrin

Financial Instruments, Recurring and Nonrecurring Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]
Financial Instruments, Recurring and Nonrecurring Fair Value Measurements
	5	Financial Instruments, Recurring and Nonrecurring Fair Value Measurements
	Recurring Fair Value Measurements
	The carrying amounts of the Company’s financial instruments, which include cash and cash equivalents, approximated their fair values as of September 30, 2014 and December 31, 2013 due to the short-term nature of these financial instruments and are considered Level 1 investments. Level 1 investments are investments where there are quoted prices in active markets available for identical assets or liabilities. Accounts receivable, accounts payable, accrued liabilities and capital lease obligations approximated their fair values at September 30, 2014 and December 31, 2013 due to the short-term nature of these financial instruments.
	The Company’s convertible senior notes, 2021 senior notes, and the Term Loan B Credit Facility are considered Level 1 instruments. The fair values of the convertible senior notes, 2021 senior notes, and the Term Loan B Credit Facility were estimated based on the most recent quoted prices for such notes.
	The fair value of the contingent consideration liability, consisting of future potential milestone payments related to the Santarus, Oceana, Progenics, and Alfa delayed release acquisitions was $205.0 million and $87.3 million at September 30, 2014 and December 31, 2013, respectively. The Company considers this liability a Level 3 instrument in the fair value hierarchy, which is defined as one with significant unobservable inputs. The Company determined fair values based on the income approach using probability-weighted discounted cash flows that included probability assessments of occurrence of triggering events appropriately discounted considering the uncertainties associated with the obligation, calculated in accordance with the terms of the acquisition agreement based on management’s forecasts, and Monte-Carlo simulation models. The most significant unobservable inputs are the probability of receiving FDA approval for the relevant compounds and the subsequent commercial success of these compounds, if approved. The fair value of the related contingent consideration would be minimal if a compound does not receive FDA approval. The Company reviews the fair value of contingent consideration quarterly or whenever events or changes in circumstances occur that indicate there has been a change in the fair value.
	The change in the fair value of the contingent consideration liability during the three-month and nine-month periods ended September 30, 2014 totaled $76.5 million and $90.7 million, respectively, and was primarily due to an increase in the fair value of the future potential milestone payments associated with the Progenics acquisition due to the September 29, 2014 FDA approval of Relistor for the treatment of OIC in patients taking opioids for chronic non-cancer pain, as well as a corresponding increase in the probability of approval of chronic non-cancer pain and oral and a decrease in the discount rates.
	Nonrecurring Fair Value Measurements
	The Company’s non-financial assets, such as goodwill, product rights and intangible assets and property and equipment, are measured at fair value when there is an indicator of impairment, or at least annually, and recorded at fair value only when an impairment charge is recognized. In the event of an impairment, the Company determines the fair value of the goodwill, product rights and intangible assets and property and equipment using a discounted cash flow approach, which contains significant unobservable inputs and therefore is considered a Level 3 fair value measurement. The unobservable inputs in the analysis generally include future cash flow projections and a discount rate.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2014
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	6	Cash and Cash Equivalents
	The Company considers all highly liquid investments with maturities from date of purchase of three months or less to be cash equivalents. The Company maintains its cash and cash equivalents in several different financial instruments with various banks and brokerage houses. This diversification of risk is consistent with Company policy to maintain liquidity and ensure the safety of principal. At September 30, 2014 and December 31, 2013, cash and cash equivalents consisted primarily of demand deposits, overnight investments in Eurodollars, certificates of deposit and money market funds at reputable financial institutions and did not include any auction rate securities. Restricted cash of $750 million at December 31, 2013 represented the gross proceeds from the sale of our 2021 Notes on December 27, 2013, which was held in escrow to finance a portion of the consideration for our acquisition of Santarus, and was disbursed in connection with the closing on January 2, 2014.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]
Inventory	7	Inventory
	The Company states raw materials, work-in-process and finished goods inventories at the lower of cost (which approximates actual cost on a first-in, first-out cost method) or market value. In evaluating whether inventory is stated at the lower of cost or market, management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time required to sell such inventory, remaining shelf life, and current and expected market conditions, including levels of competition, and generic competition. The Company measures inventory adjustments as the difference between the cost of the inventory and estimated market value based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, the Company establishes a new, lower-cost basis for that inventory, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
	The Company expenses pre-approval inventory unless the Company believes it is probable that the inventory will be saleable. The Company capitalizes inventory costs associated with marketed products and certain products prior to regulatory approval and product launch, based on management’s judgment of probable future commercial use and net realizable value. Capitalization of this inventory does not begin until the product candidate is considered to have a high probability of regulatory approval, which is generally after the Company has analyzed Phase 3 data or filed an NDA. If the Company is aware of any specific risks or contingencies that are likely to impact the expected regulatory approval process or if there are any specific issues identified during the research process relating to safety, efficacy, manufacturing, marketing or labeling of the product candidate, the Company does not capitalize the related inventory. Once the Company capitalizes inventory for a product candidate that is not yet approved, the Company monitors, on a quarterly basis, the status of this candidate within the regulatory approval process. The Company could be required to expense previously capitalized costs related to pre-approval inventory upon a change in its judgment of future commercial use and net realizable value, due to a denial or delay of approval by regulatory bodies, a delay in the timeline for commercialization or other potential factors. On a quarterly basis, the Company evaluates all inventory, including inventory capitalized for which regulatory approval has not yet been obtained, to determine if any lower of cost or market adjustment is required. As it relates to pre-approval inventory, the Company considers several factors including expected timing of FDA approval, projected sales volume and estimated selling price. At September 30, 2014 and December 31, 2013, there were no amounts included in inventory related to pre-approval inventory.
	Inventory at September 30, 2014 consisted of $68.3 million of raw materials, $20.2 million of work-in-process, and $62.6 million of finished goods, and the September 30, 2014 finished goods inventory balance includes a step-up in the value of inventories acquired in the acquisition of Santarus of $0.1 million. Inventory at December 31, 2013 consisted of $61.0 million of raw materials, $11.7 million of work-in-process, and $31.5 million of finished goods.

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	8	Intangible Assets and Goodwill
	The Company’s intangible assets consist of license agreements, product rights and other identifiable intangible assets, which result from product and business acquisitions. Goodwill represents the excess purchase price over the fair value of assets acquired and liabilities assumed in a business combination.
	When the Company makes product acquisitions that include license agreements, product rights and other identifiable intangible assets, it records the purchase price of such intangibles as intangible assets, in addition to recording the value of the product related liabilities that it assumes. The Company allocates the aggregate purchase price to the fair value of the various tangible and intangible assets in order to determine the appropriate carrying value of the acquired assets and then amortizes the cost of finite lived intangible assets as an expense in its consolidated statements of comprehensive income over the estimated economic useful life of the related assets. Finite lived intangible assets consist primarily of product rights for CMPs and are amortized over their expected economic life, which is generally the patent life of the product. The Company accounts for acquired IPR&D as indefinite lived intangible assets until regulatory approval or discontinuation at which time the Company evaluates impairment, converts the value to a definite lived intangible and determines the economic useful life of the asset for amortization purposes. The Company assesses the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that the carrying value might not be recoverable. The Company believes that the following factors could trigger an impairment review: significant underperformance relative to expected historical or projected future operating results; significant changes in the manner of the Company’s use of the acquired assets or the strategy for the Company’s overall business; approval of generic products; and significant negative industry or economic trends.
	In assessing the recoverability of its intangible assets, the Company must make assumptions regarding estimated future cash flows and other factors. If the estimated undiscounted future cash flows do not exceed the carrying value of the intangible assets, the Company must determine the fair value of the intangible assets. If the fair value of the intangible assets is less than the carrying value, the Company will recognize an impairment loss in an amount equal to the difference. The Company reviews goodwill and indefinite lived intangibles for impairment on an annual basis in the fourth quarter, and goodwill and other intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. As of September 30, 2014, management believed that the reporting unit was not at risk of failing step one of the goodwill impairment test.
	The following table reflects the components of all specifically identifiable intangible assets as of September 30, 2014 and December 31, 2013 (in thousands):
			September 30, 2014										December 31, 2013
			(Restated)
			Gross		Accumulated			Foreign			Net		Gross		Accumulated			Foreign		Net
			Amount		Amortization			Exchange			Carrying		Amount		Amortization			Exchange		Carrying
								Translation			Value							Translation		Value
	Goodwill		$	1,348,273	$	—		$	(9	)	$	1,348,264	$	180,905	$	—		$	4	$	180,909
	Finite lived intangible assets			2,056,367		(311,175	)		(393	)		1,744,799		490,367		(149,322	)		865		341,910
	Indefinite lived intangible assets			105,600		—			—			105,600		55,600		—			—		55,600
	Total		$	3,510,240	$	(311,175	)	$	(402	)	$	3,198,663	$	726,872	$	(149,322	)	$	869	$	578,419
	The weighted-average remaining life of our finite lived intangible assets was fourteen years and eight years at September 30, 2014 and December 31, 2013, respectively.
	As described in Note 2, on January 2, 2014 the Company completed its acquisition of Santarus. Finite lived intangible assets valued at $1,533.0 million indefinite lived intangible assets valued at $83.0 million and goodwill of $1,168.2 million were recorded in connection with this acquisition. During the three-month period ended September 30, 2014, the FDA approved Ruconest for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema. As a result, $33.0 million related to this intangible asset was transferred from indefinite lived intangible assets to finite lived intangible assets and will be amortized over 10 years, the asset’s patent life.
	Amortization expense is calculated on a straight-line basis over the estimated useful life of the asset. Amortization expense for the three-month periods ended September 30, 2014 and 2013 was $54.0 million and $11.2 million, respectively. Amortization expense for the nine-month periods ended September 30, 2014 and 2013 was $161.8 million and $33.5 million, respectively.
	In February 2011, the Company acquired an exclusive license to develop and commercialize products containing methylnaltrexone bromide, or the MNTX Compound, marketed under the name Relistor, from Progenics and a non-exclusive license to manufacture the MNTX Compound and products containing that compound in the same territory. The exclusive license is now worldwide, following Progenics’ termination of Ono Pharmaceutical Co. Ltd.’s rights in Japan. The Company paid Progenics an up-front license fee payment of $60.0 million. The Company also agreed to pay development milestone payments of up to $90.0 million contingent upon achieving specified regulatory approvals and commercialization milestone payments of up to $200.0 million contingent upon achieving specified targets for net sales. The Company must pay Progenics 60% of any revenue received from sublicensees in respect of any country outside the United States. The Company must pay Progenics royalties based on a percentage ranging from the mid- to high-teens of net sales by the Company and its affiliates of any product containing the MNTX Compound (excluding sales by ex-U.S. sublicensees).
	The Company accounted for the Progenics transaction as a business combination under the acquisition method of accounting. Under the acquisition method of accounting, the Company recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date in its consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. As of the acquisition date, the estimated fair value of the assets acquired was $113.0 million. On July 27, 2012, the Company received a Complete Response Letter, or CRL, from the FDA following its review of a Supplemental New Drug Application, or sNDA for methylnaltrexone bromide injection for subcutaneous use for the treatment of OIC in adult patients with chronic, non-cancer pain. The CRL requested additional clinical data. In October 2012 the Company and Progenics held an End-of-Review meeting with the FDA’s Division of Gastroenterology and Inborn Errors Products to better understand the contents of the CRL. Based on the results of this meeting, the Company reassessed the value of the indefinite lived intangible asset related to methylnaltrexone bromide injection for subcutaneous use for the treatment of OIC in chronic non-cancer pain and recorded a non-cash charge to earnings of $41.6 million in the three-month period ended September 30, 2012. On September 29, 2014, the FDA approved Relistor SI for the treatment of OIC in patients taking opioids for chronic non-cancer pain. The Company is currently evaluating the Oral OIC development program and currently believes it will continue this program. As of September 30, 2014 and December 31, 2013, accumulated amortization for the intangible related to the currently approved indication for Relistor was $9.1 million and $7.2 million, respectively.
	In December 2011, the Company completed its acquisition of Oceana for a purchase price of approximately $303 million. Oceana has license agreements with Q-Med that provide the Company the worldwide right to commercialize Deflux and Solesta. Under a stock purchase agreement with Q-Med that was assumed in connection with this transaction, the Company is obligated to pay commercialization milestone payments of up to $45.0 million contingent upon achieving specified targets for net sales of Solesta. Additionally, the Company must pay low double-digit royalties under these license agreements based on a percentage of net sales of both Deflux and Solesta by the Company and its affiliates in the U.S. and a fixed per-unit royalty for sales of the products outside the U.S.
	The Company accounted for the Oceana transaction as a business combination under the acquisition method of accounting. Under the acquisition method of accounting, the Company recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date in its consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. As of the acquisition date, the estimated fair value of the assets acquired was approximately $342.8 million. At September 30, 2014 accumulated amortization for the Deflux intangible was $12.9 million and $79.9 million for the Solesta intangible. At December 31, 2013 accumulated amortization for the Deflux intangible was $9.3 million and $58.1 million for the Solesta intangible.
	In August 2012, the Company amended its 1996 Agreement with Alfa. The amended agreement does not alter any of the terms for the traveler’s diarrhea, or TD, or hepatic encephalopathy, or HE, indications developed under the 1996 Agreement or irritable bowel syndrome, or IBS. The Company remains obligated to pay Alfa royalties, at the same range of rates as under the 1996 Agreement, on net sales of such products. In addition, the amended agreement provides the Company with an exclusive license to develop and commercialize rifaximin products for Crohn’s disease in the United States and Canada and a non-exclusive license to develop such products worldwide. The Company paid Alfa a non-refundable upfront fee of $10.0 million in August 2012, and is obligated to make a $25.0 million milestone payment upon receipt of marketing authorization in the United States for a delayed release formulation product for Crohn’s disease, and additional milestones based on net sales of delayed release formulation products for Crohn’s disease of up to $200.0 million. In addition, the Company is required to pay Alfa royalties on sales of rifaximin products for Crohn’s disease at percentage rates ranging from the low to mid-double digits.
	The Company accounted for the Alfa transaction as a business combination under the acquisition method of accounting. Under the acquisition method of accounting, the Company recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date in its consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. As of the acquisition date, the estimated fair value of the assets acquired was $23.4 million which is included as an indefinite lived intangible asset on the consolidated balance sheet.
	From 2002 through 2007, the Company acquired the rights to several compounds and products from various pharmaceutical companies and recorded intangible assets with a gross value of $147.2 million. At September 30, 2014 and December 31, 2013, accumulated amortization for these assets was $80.0 million and $74.4 million, respectively, and their carrying value was $32.8 million and $38.2 million, respectively.

Notes

Notes	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
Notes	9	Notes
	Convertible Senior Notes Due 2028
	On August 22, 2008 the Company closed an offering of $60.0 million in Convertible Senior Notes due 2028, or the 2028 Notes. Net proceeds from the offering were $57.3 million. The 2028 Notes were governed by an indenture, dated as of August 22, 2008, between the Company and U.S. Bank National Association, as trustee.
	The 2028 Notes bore interest at a rate of 5.5% per year, payable semiannually in arrears on February 15 and August 15 of each year. The 2028 Notes were to mature on August 15, 2028, unless previously converted or repurchased in accordance with their terms prior to such date.
	In March 2012, the Company entered into a note repurchase agreement with the holder of a majority in principal amount of the 2028 Notes. The Company used a portion of the proceeds from its offering of the 2019 Notes discussed below to purchase from this holder and another holder approximately 42.1% of the 2028 Notes for an aggregate purchase price of approximately $137.2 million. The Company incurred a loss on extinguishment of debt during the three-month period ended March 31, 2012 of $14.4 million, which primarily consists of $9.3 million in estimated fair market value of the put option granted to the majority holder, $2.5 million in estimated fair market value of the notes extinguished over their book value at the extinguishment date, and $2.0 million paid to the note holder for interest that the note holders would have received through August 2013, the first date the Company could call the debt under the original debt indenture. In December 2012 one of the holders of the 2028 Notes converted notes with a par value of $22.3 million under the terms of the note indenture, and received cash equal to the par value of the notes and interest on these notes through February 15, 2013, and 1.9 million shares of common stock. The Company incurred a loss on extinguishment of debt during the three-month period ended December 31, 2012 of $1.2 million, which primarily consists of $1.1 million in estimated fair market value of the notes extinguished over their book value at the extinguishment date, and $0.1 million paid to the note holder for interest that the note holders would have received through February 2013.
	In connection with the issuance of the 2028 Notes, the Company incurred $2.7 million of issuance costs, which primarily consisted of investment banker, legal and other professional fees. These costs are being amortized and were recorded as additional interest expense through August 2013, the first scheduled date on which holders have the option to require the Company to repurchase the 2028 Notes.
	The Company separately accounted for the liability and equity components of the convertible debt instrument by allocating the proceeds from issuance of the 2028 Notes between the liability component and the embedded conversion option, or equity component. This allocation was done by first estimating an interest rate at the time of issuance for similar notes that do not include the embedded conversion option. This interest rate of 12.5% was used to compute the initial fair value of the liability component of $44.1 million.
	The excess of the initial proceeds received from the convertible 2028 Notes over the initial amount allocated to the liability component, of $15.9 million, is allocated to the embedded conversion option, or equity component. This excess was reported as a debt discount and subsequently amortized as interest cost, using the interest method, through August 2013, the first scheduled date on which the holders had the option to require the Company to repurchase the 2028 Notes.
	The Company had the right to redeem the 2028 Notes, in whole or in part, at any time after August 15, 2013 for cash equal to the principal amount of the Notes to be redeemed, plus any accrued and unpaid interest. The Company called the 2028 Notes for redemption in September 2013, but before the redemption date, the holders elected to convert the remaining 2028 Notes with a par value of $12.5 million under the terms of the note indenture, and the holders received cash equal to the par value of the notes and interest on these notes through August 15, 2013, and 1.2 million shares of common stock.
	Convertible Senior Notes Due 2015
	On June 3, 2010 the Company closed an offering of $345.0 million in convertible senior notes due May 15, 2015, or the 2015 Notes. Net proceeds from the offering were approximately $334.2 million. The 2015 Notes are governed by an indenture, dated as of June 3, 2010 between the Company and U.S. Bank National Association, as trustee.
	The 2015 Notes bear interest at a rate of 2.75% per year, payable semiannually in arrears on May 15 and November 15 of each year. The 2015 Notes will mature on May 15, 2015, unless earlier converted or repurchased in accordance with their terms prior to such date.
	The 2015 Notes are senior unsecured obligations, and rank (i) equally to any of the Company’s existing and future unsecured senior debt, (ii) senior to any of the Company’s future indebtedness that is expressly subordinated to these 2015 Notes, and (iii) effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness.
	Upon issuance, the 2015 Notes were convertible into approximately 7,439,000 shares of the Company’s common stock under certain circumstances prior to maturity at a conversion rate of 21.5592 shares per $1,000 principal amount of 2015 Notes, which represents a conversion price of approximately $46.38 per share, subject to adjustment under certain conditions. Holders may submit their 2015 Notes for conversion at their option at specified times prior to the maturity date of May 15, 2015 only if: (1) the last reported sale price of the Company’s common stock for at least 20 trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is equal to or more than 130% of the conversion price of the 2015 Notes on the last day of such preceding fiscal quarter; (2) the trading price for the 2015 Notes, per $1,000 principal amount, for each such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate of the 2015 Notes on such date; or (3) the Company enters into specified corporate transactions. The first of these conditions had been met as of the fiscal quarter ended September 30, 2014. The 2015 Notes will be convertible, at the option of the noteholders, regardless of whether any of the foregoing conditions have been satisfied, on or after January 13, 2015 at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date of May 15, 2015. Upon conversion, the Company may pay cash, shares of the Company’s common stock or a combination of cash and stock, as determined by the Company in its discretion. On July 3, 2014, the Company notified the trustee that it had elected to satisfy the principal in cash and any conversion obligation related to the 2015 Notes submitted for conversion on or after July 3, 2014 by paying a combination of cash and stock. The notes are classified as current liabilities, with the unamortized debt discount presented as unamortized debt discount due on conversion in the mezzanine equity section of the Consolidated Balance Sheet, which was reclassified from additional paid-in-capital. The current portion of convertible senior notes and the unamortized debt discount due on conversion represent the cash required for the principal payment.
	The Company is required to separately account for the liability and equity components of the convertible debt instrument by allocating the proceeds from issuance of the 2015 Notes between the liability component and the embedded conversion option, or equity component. This allocation was done by first estimating an interest rate at the time of issuance for similar notes that do not include the embedded conversion option. This interest rate of 8.35% was used to compute the initial fair value of the liability component of $265.6 million. The excess of the initial proceeds received from the convertible 2015 Notes over the initial amount allocated to the liability component, of $79.4 million, is allocated to the embedded conversion option, or equity component. This excess is reported as a debt discount and subsequently amortized as interest cost, using the interest method, through May 2015, the maturity date of the 2015 Notes.
	In connection with the issuance of the 2015 Notes, the Company incurred $10.8 million of issuance costs, which primarily consisted of investment banker, legal and other professional fees. The portion of these costs related to the equity component of $2.5 million was charged to additional paid-in capital. The portion of these costs related to the debt component of $8.3 million is being amortized and are recorded as additional interest expense through May 2015, the maturity date of the 2015 Notes.
	In connection with the issuance of the 2015 Notes, the Company entered into capped call transactions with certain counterparties covering approximately 7,439,000 shares of the Company’s common stock. The capped call transactions have a strike price of $46.38 and a cap price of $62.44, and are exercisable when and if the 2015 Notes are converted. If upon conversion of the 2015 Notes, the price of the Company’s common stock is above the strike price of the capped calls, the counterparties will deliver shares of the Company’s common stock and/or cash with an aggregate value approximately equal to the difference between the price of the Company’s common stock at the conversion date (as defined, with a maximum price for purposes of this calculation equal to the cap price) and the strike price, multiplied by the number of shares of the Company’s common stock related to the capped call transactions being exercised. The Company paid $44.3 million for these capped calls and charged this to additional paid-in capital.
	The carrying value of the equity component related to the 2015 Notes at September 30, 2014 and December 31, 2013 was $79.4 million. The effective interest rate on the liability component for the three-month and nine-month periods ended September 30, 2014 and 2013 was 8.35%. Total interest cost of $7.3 million and $7.0 million was recognized during the three-month periods ended September 30, 2014 and 2013, respectively, including $4.5 million and $4.2 million of amortization of debt discount, respectively. Total interest cost of $21.7 million and $20.7 million was recognized during the nine-month periods ended September 30, 2014 and 2013, respectively, including $13.4 million and $12.3 million of amortization of debt discount, respectively. The fair value of the 2015 Notes was approximately $1,164.4 million at September 30, 2014.
	Convertible Senior Notes Due 2019
	On March 16, 2012 the Company closed an offering of $690.0 million in convertible senior notes due March 15, 2019, or the 2019 Notes. Net proceeds from the offering were approximately $668.3 million. The 2019 Notes are governed by an indenture, dated as of March 16, 2012 between the Company and U.S. Bank National Association, as trustee.
	The 2019 Notes bear interest at a rate of 1.50% per year, payable semiannually in arrears on March 15 and September 15 of each year. The 2019 Notes will mature on March 15, 2019, unless earlier converted or repurchased in accordance with their terms prior to such date.
	The 2019 Notes are senior unsecured obligations, and rank (i) equally to any of the Company’s existing and future unsecured senior debt, (ii) senior to any of the Company’s future indebtedness that is expressly subordinated to these 2019 Notes, and (iii) effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness.
	Upon issuance, the 2019 Notes were convertible into approximately 10,484,000 shares of the Company’s common stock under certain circumstances prior to maturity at a conversion rate of 15.1947 shares per $1,000 principal amount of 2019 Notes, which represents a conversion price of approximately $65.81 per share, subject to adjustment under certain conditions. Holders may submit their 2019 Notes for conversion at their option at specified times prior to the maturity date of March 15, 2019 only if: (1) the last reported sale price of the Company’s common stock for at least 20 trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is equal to or more than 130% of the conversion price of the 2019 Notes on the last day of such preceding fiscal quarter; (2) the trading price for the 2019 Notes, per $1,000 principal amount, for each such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate of the 2019 Notes on such date; or (3) the Company enters into specified corporate transactions. The first of these conditions had been met as of the fiscal quarter ended September 30, 2014. The 2019 Notes will be convertible, at the option of the noteholders, regardless of whether any of the foregoing conditions have been satisfied, on or after November 9, 2018 at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date of March 15, 2019. Upon conversion, the Company may pay cash, shares of the Company’s common stock or a combination of cash and stock, as determined by the Company in its discretion. On July 3, 2014, the Company notified the trustee that it had elected to satisfy the principal in cash and any conversion obligation related to the 2019 Notes submitted for conversion on or after July 3, 2014 by paying a combination of cash and stock. Because of this election, the notes are now classified as current liabilities, with the unamortized debt discount presented as unamortized debt discount due on conversion in the mezzanine equity section of the Consolidated Balance Sheet, which was reclassified from additional paid-in-capital. The current portion of convertible senior notes and the unamortized debt discount due on conversion represent the cash required for the principal payment.
	The Company is required to separately account for the liability and equity components of the convertible debt instrument by allocating the proceeds from issuance of the 2019 Notes between the liability component and the embedded conversion option, or equity component. This allocation was done by first estimating an interest rate at the time of issuance for similar notes that do not include the embedded conversion option. This interest rate of 5.50% was used to compute the initial fair value of the liability component of $529.3 million. The excess of the initial proceeds received from the convertible 2019 Notes over the initial amount allocated to the liability component, of $160.7 million, is allocated to the embedded conversion option, or equity component. This excess is reported as a debt discount and subsequently amortized as interest cost, using the interest method, through March 2019, the maturity date of the 2019 Notes.
	In connection with the issuance of the 2019 Notes, the Company incurred $21.7 million of issuance costs, which primarily consisted of investment banker, legal and other professional fees. The portion of these costs related to the equity component of $5.1 million was charged to additional paid-in capital. The portion of these costs related to the debt component of $16.6 million is being amortized and is recorded as additional interest expense through March 2019, the maturity date of the 2019 Notes.
	In connection with the issuance of the 2019 Notes, the Company entered into convertible bond hedge transactions with certain counterparties covering approximately 10,484,000 shares of the Company’s common stock. The convertible bond hedge transactions have a strike price of $65.81 and are exercisable when and if the 2019 Notes are converted. If upon conversion of the 2019 Notes, the price of the Company’s common stock is above the strike price of the convertible bond hedge transactions, the counterparties will deliver shares of the Company’s common stock and/or cash with an aggregate value approximately equal to the difference between the price of the Company’s common stock at the conversion date and the strike price, multiplied by the number of shares of the Company’s common stock related to the convertible bond hedge transaction being exercised. The Company paid $167.0 million for these convertible bond hedge transactions and charged this to additional paid-in capital.
	Simultaneously with entering into the convertible bond hedge transactions, the Company entered into privately negotiated warrant transactions whereby the Company sold the counterparties to these transactions warrants to acquire, subject to customary adjustments, approximately 10,484,000 shares of the Company’s common stock at a strike price of $85.31 per share, also subject to adjustment. The Company received $99.0 million for these warrants and credited this amount to additional paid-in capital.
	The carrying value of the equity component related to the 2019 Notes at September 30, 2014 and December 31, 2013 was $160.7 million. The effective interest rate on the liability component for the three-month and nine-month periods ended September 30, 2014 and 2013 was 5.50%. Total interest cost of $8.5 million and $8.3 million was recognized during the three-month periods ended September 30, 2014 and 2013, respectively, including $5.4 million and $5.1 million of amortization of debt discount, respectively. Total interest cost of $25.4 million and $24.5 million was recognized during the nine-month periods ended September 30, 2014 and 2013, respectively, including $15.9 million and $15.0 million of amortization of debt discount, respectively. The fair value of the 2019 Notes was approximately $1,675.0 million at September 30, 2014.
	The following table summarizes information on the convertible senior notes as of (in thousands):
			September 30,			December 31,
			2014			2013
	Convertible Senior Notes due 2015:
	Principal amount of the liability component		$	344,974		$	345,000
	Unamortized discount			(13,009	)		(26,356	)
	Net carrying amount		$	331,965		$	318,644
	Convertible Senior Notes due 2019:
	Principal amount of the liability component		$	690,000		$	690,000
	Unamortized discount			(110,702	)		(126,594	)
	Net carrying amount		$	579,298		$	563,406
	Total Convertible Senior Notes
	Principal amount of the liability component		$	1,034,974		$	1,035,000
	Unamortized discount			(123,711	)		(152,950	)
	Net carrying amount		$	911,263		$	882,050
	Notes Due 2021
	On December 27, 2013 the Company completed the issuance and sale of $750.0 million in aggregate principal amount of 6.00% senior notes due 2021, or the 2021 Notes, in a private placement. As explained below, additional interest on the 2021 Notes may begin to accrue under certain circumstances. The 2021 Notes will mature on January 15, 2021 and bear interest at a rate of 6.00% per annum, accruing from December 27, 2013. Interest is payable on the 2021 Notes on each January 15 and July 15, commencing July 15, 2014. The 2021 Notes were issued at 100% of face value and the net proceeds to the Company from the sale of the 2021 Notes were $723.0 million after deducting the initial purchasers’ discounts and offering expenses, which were recorded in 2014 upon the completion of our acquisition of Santarus. The 2021 Notes are governed by terms contained in an indenture, dated as of December 27, 2013, between the Company and U.S. Bank National Association, as trustee.
	Upon closing, the Company placed the gross proceeds from the sale of the 2021 Notes into a secured escrow account, and they were recorded as restricted cash on the consolidated balance sheet at December 31, 2013. As discussed in Note 2, the Company completed its tender offer for all outstanding shares of common stock of Santarus, at a purchase price of $32.00 per share on January 2, 2014. Concurrently with completion of the tender offer, the proceeds in the escrow account were released to fund the acquisition. The 2021 Notes are unsecured obligations of the Company. Promptly following the acquisition of Santarus, Santarus and certain current subsidiaries of the Company became guarantors of the 2021 Notes on a senior unsecured basis.
	At any time prior to January 15, 2017, the Company may, at its option, redeem some or all of the 2021 Notes at a redemption price of 100% of the principal amount thereof, plus a make-whole premium set forth in the indenture and accrued and unpaid interest, if any, to the redemption date. Beginning January 15, 2017, the Company may redeem the 2021 Notes, in whole or in part, at redemption prices (expressed as percentages of principal amount) equal to 104.5%, 103.0%, 101.5% and 100.0% for the 12-month periods beginning on January 15, 2017, January 15, 2018, January 15, 2019 and January 15, 2020, respectively, plus accrued and unpaid interest, if any. At any time prior to January 15, 2017, the Company also may redeem up to 35% of the principal amount of the 2021 Notes at a redemption price equal to 106.00% of the principal amount thereof plus accrued and unpaid interest, if any, with the net cash proceeds of certain equity offerings.
	The indenture contains covenants that restrict the ability of the Company and certain of its subsidiaries to, among other things: (i) borrow money or issue preferred stock; (ii) pay dividends or make other payments or distributions on equity or purchase, redeem or otherwise acquire equity; (iii) make principal payments on, or purchase or redeem subordinated indebtedness prior to any scheduled principal payment or maturity; (iv) make certain investments; (v) create liens on their assets; (vi) sell their assets; (vii) enter into certain transactions with affiliates; (viii) engage in unrelated businesses and (ix) consolidate, merge or sell substantially all of the Company’s assets. These covenants are subject to a number of exceptions and qualifications, including the fall away of certain of these covenants if the 2021 Notes receive an investment grade credit rating in the future. The indenture also requires the Company to make an offer to repurchase the 2021 Notes upon the occurrence of certain events constituting either a change of control that reduces the Company’s credit rating or asset sales in specified circumstances. The fair value of the 2021 Notes was approximately $813.8 million at September 30, 2014.
	Concurrently with the issuance of the 2021 Notes, the Company, the guarantors, and Jefferies LLC, as the representative of the initial purchasers of the 2021 Notes, entered into a registration rights agreement whereby the Company and the guarantors agreed to file with the Securities and Exchange Commission a registration statement relating to a registered offer to exchange the 2021 Notes for a new series of the Company’s notes in the same aggregate principal amount as, and with terms substantially identical in all respects to, the 2021 Notes. If an exchange offer registration statement for the 2021 Notes is not declared effective by November 27, 2014 or if the Company does not complete an exchange offer by December 26, 2014, additional interest will begin to accrue on the notes at a rate of 0.25% per year from the triggering date to the first 90-day period after such date. The amount of additional interest will increase by an additional 0.25% per year for each subsequent 90-day period during which the exchange offer registration statement is not declared effective or the exchange offer is not completed, up to a maximum of 1.00% per year.

Credit_Agreement

Credit Agreement	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
Credit Agreement	10	Credit Agreement
	On January 2, 2014, the Company entered into a credit agreement, or the Credit Agreement, with Jefferies Finance LLC, as collateral agent, or the Collateral Agent, and administrative agent, and the lenders party thereto, providing for (i) a $1.2 billion six year senior secured term loan facility, or the Term Loan B Facility, and (ii) a $150.0 million five year senior secured revolving credit facility, or the Revolving Credit Facility, and together with the Term Loan B Facility, the Senior Secured Facilities. The proceeds of the Term Loan B Facility were used to fund a portion of the purchase price of the tender offer for Santarus. The proceeds of the Revolving Credit Facility can be used in the future for working capital and general corporate purposes, including permitted investments and acquisitions.
	In connection with the entry by the Company into the Credit Agreement, the Company and Oceana, Santarus, and Salix Pharmaceuticals, Inc., collectively referred to as the Guarantors, have entered into a Guarantee and Collateral Agreement, dated January 2, 2014, or the Guarantee and Collateral Agreement, with the Collateral Agent, pursuant to which (i) each of the Guarantors has guaranteed the obligations of the Company under the Credit Agreement and the obligations of each of the other Guarantors under the Guarantee and Collateral Agreement and (ii) the Company and each of the Guarantors has granted to the Collateral Agent, for the benefit of the lenders under the Credit Agreement, a first priority security interest in substantially all of its assets.
	The term loans under the Term Loan B Facility are subject to quarterly amortization equal to 1.25% of the original aggregate principal amount thereof and the remaining principal balance is due and payable on January 2, 2020 unless earlier prepaid. The Senior Secured Facilities bear interest at an annual rate of, at the Company’s option, either (i) Adjusted LIBOR (as defined by the Credit Agreement), with a floor of 1.00%, plus a margin of 3.25% or (ii) the highest of (A) the Wall Street Journal’s published “U.S. Prime Lending Rate,” (B) the Federal Funds Effective Rate (as defined by the Credit Agreement) in effect on such day plus 0.50%, (C) one-month Adjusted LIBOR plus 1.00% per annum and (D) 2.00%, in each case plus a margin of 2.25%. If the ratio of the Company’s consolidated total debt to consolidated EBITDA, or the Total Leverage Ratio, is less than 3.75 to 1.00, the margins will be reduced by 25 basis points.
	The Company is required to prepay term loans under the Term Loan B Facility with (i) 100% of the proceeds of asset sales not reinvested within generally one year, (ii) 100% of the proceeds from certain debt financings and (iii) 50% of Excess Cash Flow (as defined in the Credit Agreement). The percentage of Excess Cash Flow that must be used to prepay the Term Loan B Facility decreases to 25% if the Total Leverage Ratio is less than 3:50 to 1:00 and to zero if the Total Leverage Ratio is less than 2:50 to 1:00. The Company made no prepayments during the nine-month period ended September 30, 2014.
	The Credit Agreement includes customary affirmative and negative covenants, including restrictions on additional indebtedness, liens, investments, asset sales, stock buybacks and dividends, mergers, consolidations, and transactions with affiliates and capital expenditures. The negative covenants are generally subject to various exceptions. The Credit Agreement does not include any financial maintenance covenants, with the exception that if 25% or more of the Revolving Credit Facility is being utilized, a Total Leverage Ratio requirement (measured as of the last day of each quarter), which decreases over time, must be satisfied. The Company was in compliance with these covenants as of September 30, 2014. The carrying value of the term loans under the Term Loan B Facility approximated their fair value as of September 30, 2014.

Research_and_Development

Research and Development	9 Months Ended
	Sep. 30, 2014
Research and Development [Abstract]
Research and Development	11	Research and Development
	The Company expenses research and development costs, both internal and externally contracted, as incurred. For nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities, the Company initially capitalizes the advance payment. The Company then recognizes such amounts as an expense as the related goods are delivered or the related services are performed. At September 30, 2014 and December 31, 2013, the net liability related to on-going research and development activities was $15.1 million and $11.8 million, respectively.

Comprehensive_Income

Comprehensive Income	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]
Comprehensive Income	12	Comprehensive Income
	Other comprehensive income is composed entirely of adjustments resulting from the translation of the financial statements of the Company’s foreign subsidiary, Oceana into U.S. dollars.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]
Stockholders' Equity	13	Stockholders’ Equity
	Additional Paid-In Capital
	The following table summarizes the activity in additional paid-in-capital for the nine-month periods ended September 30 (in thousands):
			2014			2013
			(Restated)
	Balance at December 31		$	667,428		$	631,364
	Issuance of common stock upon exercise of stock options			5,572			3,470
	Payments related to net settlement of stock-based awards			(7,329	)		(4,037	)
	Excess tax benefit from stock-based compensation			16,214			8,287
	Compensation expense related to restricted stock awards			27,590			18,832
	Reclassification of unamortized debt discount due on conversion of senior notes			(123,711	)		—
	Balance at September 30		$	585,764		$	657,916
	Share-Based Compensation
	At September 30, 2014, the Company had one active share-based compensation plan, the 2014 Stock Plan, which was approved and adopted during the second quarter of 2014, allowing for the issuance of stock options and restricted stock. The Company estimates the fair value of share-based payment awards on the date of the grant. The Company recognizes cost over the period during which an employee is required to provide service in exchange for the award.
	Starting in 2006, the Company began issuing restricted shares to employees, executives and directors of the Company. The restrictions on the restricted stock lapse according to one of two schedules. For employees and executives of the Company, restrictions lapse 25% annually over four years or 33% over 3 years. For members of the Company’s Board of Directors, restrictions lapse 100% after approximately one year. The fair value of the restricted stock was estimated using an assumed forfeiture rate of 9.4% and is being expensed on a straight-line basis over the period during which the restrictions lapse. For the three-month periods ended September 30, 2014 and 2013, the Company recognized $11.2 million and $6.8 million in share based compensation expense related to the restricted shares, respectively. For the nine-month periods ended September 30, 2014 and 2013, the Company recognized $27.6 million and $18.8 million in share based compensation expense related to the restricted shares, respectively. As of September 30, 2014, the total amount of unrecognized compensation cost related to nonvested restricted stock awards, to be recognized as expense subsequent to September 30, 2014, was approximately $114.3 million, and the related weighted-average period over which it is expected to be recognized is approximately 3 years.
	Aggregate stock plan activity is as follows:
			Total Shares			Stock Options					Restricted Shares					Stock Options and
			Available													Restricted Shares
			For Grant			Number			Weighted		Number			Weighted		Number			Weighted
									Average		Subject to			Average					Average
									Price		Issuance			Price					Price
	Balance at December 31, 2013			3,031,539			498,493		$	18.23		1,472,255		$	46.91		1,970,748		$	39.66
	Granted			(963,071	)		—					963,071		$	125.27		963,071		$	125.27
	Exercised			—			(299,816	)		18.58		—			—		(299,816	)	$	18.58
	Vested			—			—			—		(480,537	)	$	37.56		(480,537	)	$	37.56
	Additional shares authorized			1,500,000			—			—		—			—		—			—
	Canceled			125,612			(4,517	)		23.87		(121,095	)	$	87.1		(125,612	)	$	84.83
	Balance at September 30, 2014			3,694,080			194,160		$	17.56		1,833,694		$	87.86		2,027,854		$	81.13
	For the nine-month period ended September 30, 2014, the Company issued 0.3 million shares of the Company’s common stock with a market value of $33.2 million upon the exercise of stock options. For the nine-month period ended September 30, 2013, the Company issued 0.2 million shares of the Company’s common stock with a market value of $12.2 million upon the exercise of stock options. The Company recognized no share-based compensation expense related to stock options for the three-month or nine-month periods ended September 30, 2014 or 2013, nor any income tax benefit. The total intrinsic value of options exercised for the nine-month periods ended September 30, 2014 and 2013 was $27.6 million and $8.8 million, respectively. As of September 30, 2014, there was no unrecognized compensation cost for stock options because all stock options were fully vested. For the nine-month periods ended September 30, 2014 and 2013 the Company received $5.6 million and $3.5 million in cash from stock option exercises, respectively.
	The following table summarizes stock-based compensation expense incurred (in thousands):
			Three months ended						Nine months ended
			September 30,						September 30,
			2014			2013			2014		2013
			(Restated)						(Restated)
	Research and development (as revised)		$	2,532		$	954		$	6,287	$	2,532
	Selling, general and administrative (as revised)			8,622			5,867			21,304		16,310
	Total		$	11,154		$	6,821		$	27,591	$	18,842

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Income Taxes	14	Income Taxes
	The Company provides for income taxes under the liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of differences between the tax basis of assets or liabilities and their carrying amounts in the consolidated financial statements. The Company provides a valuation allowance for deferred tax assets if it is more likely than not that these items will either expire before the Company is able to realize their benefit or if future deductibility is uncertain.
	The Company files a consolidated U.S. federal income tax return and consolidated and separate company income tax returns in many U.S. state jurisdictions. Generally, the Company is no longer subject to federal and state income tax examinations by U.S. tax authorities for years prior to 1994. During the first quarter of the current year, the Internal Revenue Service commenced an audit for the 2011 tax year. At this time we are not aware of any potential audit adjustments that will materially impact the Company’s financial statements.
	The provision for income taxes reflects the Company’s estimate of the effective tax rate expected to be applicable for the full fiscal year. The Company’s effective tax rate for the three-month periods ended September 30, 2014 and 2013 was 30.6% and 23.1%, respectively. The Company’s effective tax rate for the nine-month periods ended September 30, 2014 and 2013 was 35.2% and 30.6%, respectively. The increase in our effective tax rate for the three-month and nine-month periods ended September 30, 2014, as compared to the same periods in 2013, is due primarily to non-deductible acquisition costs that occurred during the first quarter of 2014. The Company re-evaluates this estimate each quarter based on the Company’s estimated tax expense for the year. The Company’s effective tax rate might fluctuate throughout the year due to various items including, but not limited to, certain transactions the Company enters into, settlement of uncertain tax positions, the implementation of tax planning strategies, and changes in the tax law. The Company’s effective tax rates differ from the statutory rate of 35% primarily due to state income taxes and expenses and losses which are non-deductible for federal and state income tax purposes.

Net_Income_Loss_per_Share

Net Income (Loss) per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]
Net Income (Loss) per Share	15	Net Income (Loss) per Share
	The Company computes basic net income (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding. The Company computes diluted net income (loss) per share by dividing net income (loss) by the weighted average number of common shares and dilutive common share equivalents then outstanding. Common share equivalents consist of the incremental common shares issuable upon the exercise of stock options and the impact of unvested restricted stock grants. The Company accounts for the effect of the convertible notes on diluted net income (loss) per share using the treasury stock method. As a result, the convertible notes have no effect on diluted net income per share until the Company’s stock price exceeds the conversion price of $9.25 per share for the 2028 Notes, $46.38 for the 2015 Notes, and $65.81 for the 2019 Notes. For the three-month and nine-month periods ended September 30, 2013, weighted average common shares, diluted, includes the effect of approximately 6,486,000 shares issuable upon conversion of the 2028 Notes calculated using the treasury stock method, taking into effect the repurchase in March and December 2012 and September 2013 of 2028 Notes convertible into approximately 2,730,000, 2,405,000 and 1,351,000 shares, respectively, since the Company’s average stock price exceeded $9.25 during these periods. For the three-month and nine-month periods ended September 30, 2013, weighted average common shares, diluted, includes the effect of approximately 7,439,000 shares issuable upon conversion of the 2015 Notes calculated using the treasury stock method, since the Company’s average stock price exceeded $46.38 during these periods. For the three-month period ended September 30, 2013, weighted average common shares, diluted, includes the effect of the approximately 10,484,000 shares issuable upon conversion of the 2019 Notes calculated using the treasury stock method since the Company’s average stock price exceed $65.81 during this period. For the nine-month period ended September 30, 2013, weighted average common shares, diluted, excludes the effect of the approximately 10,484,000 shares issuable upon conversion of the 2019 Notes calculated using the treasury stock method since the Company’s average stock price did not exceed $65.81 during this period. For the three-month and nine-month periods ended September 30, 2014, weighted average common shares, diluted, equaled weighted average common shares, basic, because inclusion of 283,045 and 106,291 shares of restricted stock, respectively, and the effect of approximately 7,439,000 and 10,484,000 shares issuable upon conversion of the 2015 and 2019 Notes, respectively, would have been anti-dilutive.
	For the three-month periods ended September 30, 2013, there were 21,755, potential common shares outstanding that were excluded from the diluted net income per share calculation because their effect would have been anti-dilutive. For the nine-month periods ended September 30, 2013, there were 22,020, potential common shares outstanding that were excluded from the diluted net income per share calculation because their effect would have been anti-dilutive.
	The following table reconciles the numerator and denominator used to calculate diluted net income (loss) per share (in thousands):
			Three months ended					Nine months ended
			September 30,					September 30,
			2014			2013		2014			2013
			(Restated)					(Restated)
	Numerator:
	Net income (loss)		$	(93,108	)	$	47,331	$	(127,267	)	$	90,772
	Denominator:
	Weighted average common shares, basic			63,687			61,763		63,482			61,416
	Dilutive effect of restricted stock			—			675		—			552
	Dilutive effect of convertible debt			—			3,984		—			2,625
	Dilutive effect of stock options			—			407		—			438
	Weighted average common shares, diluted			63,687			66,829		63,482			65,031

Segment_Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]
Segment Reporting	16	Segment Reporting
	The Company operates in a single industry acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases. Accordingly, the Company’s business is classified as a single reportable segment.
	The following table presents net product revenues by product category (in thousands):
			Three months ended					Nine months ended
			September 30,					September 30,
			2014			2013		2014		2013
			(Restated)					(Restated)
	Xifaxan		$	155,815		$	165,927	$	412,740	$	469,799
	Inflammatory Bowel Disease – Apriso/Uceris/Giazo/Colazal			73,126			38,321		220,199		101,927
	Diabetes – Glumetza and Cycloset			65,470			—		316,102		—
	Purgatives – OsmoPrep/MoviPrep			(1,263	)		19,232		15,404		54,108
	Zegerid			26,546			—		91,303		—
	Other – Fenoglide/Anusol/Azasan/Diuril/Pepcid/Proctocort/ Relistor/Deflux/Solesta/Fulyzaq/Metozolv			21,853			14,704		64,318		50,392
	Net product revenues		$	341,547		$	238,184	$	1,120,066	$	676,226

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	17	Recently Issued Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update, or ASU, 2014-09—Revenue from Contracts with Customers, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This ASU is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2016. Early adoption is not permitted. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.

Legal_Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	18	Legal Proceedings
	From time to time, we are involved in various litigation matters that are being defended and handled in the ordinary course of business. The assessment of whether a loss is probable or reasonably possible, and whether the loss or a range of loss is estimable, often involves a series of complex judgments about future events. Management maintains accruals for such losses that are probable of being incurred and subject to reasonable estimation. For current matters not specifically reported herein, management does not anticipate that the ultimate liabilities, if any, arising from the resolution of such current matters would have a material effect on our financial condition or results of operations. It is possible, however, that future results of operations for any particular period could be materially affected by changes in our assessment related to any of these matters.
	Product Liability Claims
	The Company is currently and might continue to be subject to product liability claims that arise through the testing, manufacturing, marketing and sale of its products, including claims related to OsmoPrep and Relistor. The Company is vigorously defending these claims and intends to continue to vigorously defend any future claims. The Company currently has product liability coverage for all of its products other than with regard to claims filed prior to August 31, 2010 relating to OsmoPrep and Visicol, but it is possible that this coverage, and any future coverage, will be insufficient for any liabilities that may arise in the future. The Company would have to assume defense of the lawsuits and be responsible for damages, fees, and expenses, if any, that are awarded against it or for amounts in excess of the Company’s product liability coverage.
	Napo Litigation
	On May 5, 2011, Napo filed a lawsuit against the Company in the Supreme Court of the State of New York, County of New York, alleging that the Company had engaged in fraudulent conduct, breached its collaboration agreement with Napo dated December 9, 2008, and breached its duty of good faith and fair dealing. Napo also sought a declaratory judgment that it had the right to terminate the collaboration agreement and sought unspecified damages in excess of $150 million. Discovery concluded in this case last year, and, on May 31, 2013 the Company filed a motion for partial summary judgment. The court heard oral arguments on the motion in August 2013. On December 24, 2013, the court entered a short-form order granting our motion for partial summary judgment, narrowing the issues in the case. Napo timely appealed that decision to the Appellate Division of the Supreme Court of the State of New York. On January 29, 2014 the Court vacated and replaced portions of the short-form order with an order continuing to grant the Company’s motion for partial summary judgment, narrowing the issues in the case. Napo appealed that decision. Trial on the claims remaining in the case commenced on February 10, 2014. On February 25, 2014 the jury rendered its verdict, concluding that Salix had complied with its contractual obligations in commercializing Fulyzaq in the United States, and thus had not breached the collaboration agreement between the parties. On May 1, 2014, Napo filed an appeal of the jury verdict. The Company continues to advance the Company’s development and commercialization plans for crofelemer in accordance with the collaboration agreement and continues to believe that Napo’s allegations are without merit and its lawsuit baseless.
	Lupin Litigation
	Currently, there are five patents that the Company believes provide coverage for Apriso, including for methods of production and use, until 2022 (U.S. Patent Nos. 6,551,620, or the ‘620 patent, 7,547,451, or the ‘451 patent, 8,337,886, or the ‘886 patent, 8,496,965, or the ‘965 patent, and 8,865,688, or the ‘688 patent). The Company and Dr. Falk Pharma previously brought a patent infringement suit against Lupin Ltd. and Lupin Pharmaceuticals, Inc., collectively Lupin, in the U.S. District Court for the District of Delaware, alleging infringement of the ‘620 patent, the ‘965 patent, the ‘886 patent, and the ‘451 patent, based on Lupin’s filing of an Abbreviated New Drug Application, or ANDA, seeking approval to market and sell a generic version of Apriso before the expiration of these patents. In September 2014, the Company and Dr. Falk Pharma entered into an agreement with Lupin settling this litigation. Under the settlement agreement, Lupin will be permitted, if its ANDA is approved, to begin marketing a generic version of Apriso in October 2022 or earlier in certain circumstances. The parties filed a Consent Judgment and Dismissal on September 12, 2014, and it was entered by the court on September 16, 2014.
	Novel Litigation
	On February 18, 2014, the Company and Dr. Falk Pharma filed a patent infringement complaint against Novel Laboratories, or Novel, in the U.S. District Court for the District of Delaware. The complaint alleges infringement of the ‘620 patent, the ‘886 patent, and the ‘965 patent based on Novel’s filing of an ANDA seeking approval to market and sell a generic version of Apriso before the expiration of these patents. The filing of this suit within the 45-day response period provided by the Hatch-Waxman Act imposes a 30-month stay of approval of Novel’s ANDA unless the court finds in Novel’s favor prior to that time. The court has scheduled a pretrial evidentiary hearing, known as a Markman hearing, for May 2015 and a trial has been scheduled for November 2015. The Company continues to evaluate its intellectual property protecting Apriso, in which the Company has full confidence. The Company intends to vigorously enforce its intellectual property rights. Currently, the Company cannot predict or determine the timing or outcome of this inquiry or its impact on financial condition or results of operations.
	Par Litigation
	On July 17, 2014, the Company filed a patent infringement complaint against Par Pharmaceutical Companies, Inc., or Par, et al in the U.S. District Court for the District of Delaware. This is a civil action for infringement of U.S. Patent No. 6,197,341, or the ‘341 patent, and U.S. Patent No. 8,497,256, or the ‘256 patent, based on Par’s filing of an ANDA seeking approval to market and sell a generic version of Giazo before the expiration of these patents. The filing of this suit within the 45-day response period provided by the Hatch-Waxman Act imposes a 30-month stay of approval of Par’s ANDA unless the court finds in Par’s favor prior to that time. The Company continues to evaluate its intellectual property protecting Giazo, in which the Company has full confidence. The Company intends to vigorously enforce its intellectual property rights.
	Mylan Litigation
	On August 15, 2014 the Company filed a Complaint against Mylan Pharmaceuticals, Inc., or Mylan, in the U.S. District Court for the District of Delaware. This is a civil action for infringement of the ‘341 patent and the ‘256 patent based on Mylan’s filing of an ANDA seeking approval to market and sell a generic version of Giazo before the expiration of these patents. The filing of this suit within the 45-day response period provided by the Hatch-Waxman Act imposes a 30-month stay of approval of Par’s ANDA unless the court finds in Mylan’s favor prior to that time. On September 5, 2014, Mylan filed a Motion to Dismiss for Lack of Jurisdiction Over the Person. In response, on September 8, 2014, the Company filed a complaint against Mylan in the Northern District of West Virginia, also within the 45-day response period provided by the Hatch-Waxman. The Company continues to evaluate its intellectual property protecting Giazo, in which the Company has full confidence. The Company intends to vigorously enforce its intellectual property rights.
	DOJ Subpoena
	On February 1, 2013, the Company’s wholly owned subsidiary Salix Pharmaceuticals, Inc. received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents regarding the Company’s sales and promotional practices for its Xifaxan, Relistor and Apriso products. The Company is continuing to respond to the subpoena and intends to cooperate fully with the subpoena and related government investigation. Currently, the Company cannot predict or determine the timing or outcome of this inquiry or its impact on financial condition or results of operations.
	Santarus Shareholder Litigation
	Beginning on November 12, 2013, eleven putative class action lawsuits were filed by shareholders of Santarus seeking to challenge the Company’s proposed acquisition of Santarus, which was announced on November 7, 2013. Nine of these actions were filed in the Delaware Court of Chancery, one was filed in California Superior Court (San Diego County) and one was filed in the U.S. District Court for the Southern District of California. These actions generally allege that the members of the Santarus board of directors breached their fiduciary duties to Santarus shareholders by failing to maximize the value of Santarus and by making inadequate or misleading disclosures regarding the proposed merger, and that Santarus, we and certain of our subsidiaries aided and abetted those breaches of fiduciary duty. The complaint in the action pending in California federal court also asserts causes of action on behalf of the individual plaintiff for alleged violations of certain sections of the Exchange Act. These actions generally sought, among other things, to enjoin the merger, unspecified damages and fees. On December 9, 2013, Santarus and its directors filed a motion to stay the action pending in California Superior Court. On December 11, 2013, the Delaware Court of Chancery consolidated the nine actions pending in that court, appointed lead counsel for the plaintiffs, and designated the amended complaint filed by plaintiff Imad Ahmad Khalil on December 9, 2013 as the operative complaint in the consolidated Delaware litigation. On December 20, 2013, the parties in the Delaware litigation reached an agreement in principle, subject to full documentation, to resolve the plaintiffs’ claims in that action in exchange for certain supplemental disclosures that Santarus included in an amended Schedule 14D-9 it filed on that date. The Company completed its merger with Santarus on January 2, 2014. The parties in the Delaware litigation executed a Memorandum of Understanding reflecting the terms of their agreement in principle on January 17, 2014, completed confirmatory discovery in February 2014 and are currently attempting to finalize the settlement. The settlement of the Delaware litigation will be subject to approval by the Delaware Court of Chancery. The plaintiffs’ counsel in the Delaware litigation has also indicated that the plaintiffs intend to request an award of attorneys’ fees from the Delaware Court of Chancery. On January 22, 2014, Santarus and its directors filed a renewed motion to stay the action pending in California Superior Court, and the Company filed a separate motion to stay that action in favor of the Delaware litigation. On January 22, 2014, Santarus and its directors filed a motion to stay the action pending in the California federal court in favor of the Delaware litigation, and we filed a joinder in support of that motion on January 23, 2014. On February 12, 2014, the parties in the action pending in California federal court filed a joint motion to stay that action pending a decision by the Delaware Court of Chancery regarding final approval of the proposed settlement of the Delaware litigation, and the California federal court granted that motion on February 13, 2014. On August 11, 2014, the parties in the action pending in California Superior Court filed a stipulation memorializing their agreement to stay that action pending a decision by the Delaware Court of Chancery regarding final approval of the proposed settlement of the Delaware litigation, and the California Superior Court granted the parties’ request for a stay on August 18, 2014. The Company is attempting to finalize the settlement of the consolidated Delaware litigation as described above. The Company believes that all of the claims asserted against it by Santarus shareholders lack merit.
	Cosmo Transaction Shareholder Litigation
	On July 18, 2014, Erste-Sparinvest Kapitalanlagegesellschaft M.B.H., a purported shareholder of the Company, filed a putative class action in the Delaware Court of Chancery against the Company, its directors, Cosmo Pharmaceuticals S.p.A., or Cosmo, Cosmo Tech and Sangiovese, LLC (Case No. 9909, Delaware Chancery Court). The Erste-Sparinvest complaint alleges that the Company’s directors breached their fiduciary duties in connection with the proposed merger contemplated by the agreement and plan of merger and reorganization announced on July 8, 2014 among the Company, Cosmo, Cosmo Tech and Sangiovese, LLC. The complaint also alleges that the entity defendants aided and abetted those breaches. The complaint seeks, among other relief, an order permanently enjoining the merger and damages in an unspecified amount. On August 26, 2014, Michael M. Cebrik, another purported shareholder of the Company, filed a second putative class action in the Delaware Court of Chancery seeking to enjoin the proposed merger among the Company, Cosmo, Cosmo Tech and Sangiovese, LLC. The Cebrik complaint names the same defendants as the Erste-Sparinvest complaint, asserts substantially similar claims and seeks the same remedies. On October 1, 2014, plaintiffs’ counsel submitted a letter to the Delaware Court of Chancery requesting consolidation of the Erste-Sparinvest and Cebrik actions and appointment of co-lead counsel, and the Delaware Court of Chancery granted plaintiffs’ request later the same day.
	On October 3, 2014, the Company announced that it had reached an agreement with Cosmo to terminate its previously-announced merger agreement. Under the terms of the termination, the Company made a $25 million payment to Cosmo. On October 16, 2014, following the termination of the merger agreement challenged in the consolidated Delaware action, the plaintiffs voluntarily dismissed their claims without prejudice. On October 22, 2014, the Delaware court approved the dismissal of plaintiffs’ claims.
	Zegerid Rx and Zegerid OTC Patent Litigation
	Zegerid Rx Litigation
	In April 2010, the U.S. District Court for the District of Delaware ruled that five patents covering Zegerid capsules and Zegerid powder for oral suspension (U.S. Patent Nos. 6,489,346; 6,645,988; 6,699,885; 6,780,882; and 7,399,772) were invalid due to obviousness. These patents were the subject of lawsuits Santarus filed in 2007 against Par, in response to ANDAs filed by Par with the FDA. The University of Missouri, licensor of the patents, is joined in the litigation as a co-plaintiff. In May 2010, Santarus filed an appeal of the District Court’s ruling to the U.S. Court of Appeals for the Federal Circuit. Following the District Court’s decision, Par launched its generic version of Zegerid capsules in June 2010.
	In September 2012, the U.S. Court of Appeals for the Federal Circuit reversed in part the April 2010 decision of the District Court. The Federal Circuit found that certain claims of U.S. Patent Nos. 6,780,882, or the ‘882 patent and 7,399,772, or the ‘772 patent, which Par had been found to infringe, were not invalid due to obviousness. The Federal Circuit affirmed the District Court’s finding of invalidity for the asserted claims from the remaining three patents. Following the Federal Circuit’s decision, Par announced that it had ceased distribution of its generic Zegerid capsules product in September 2012. In December 2012, the Federal Circuit remanded the case to the District Court for further proceedings pertaining to damages. In February 2013, Santarus filed an amended complaint with the District Court for infringement of the ‘882 patent and the ‘772 patent and requested a jury trial with respect to the issue of damages in connection with Par’s launch of its generic version of Zegerid capsules in June 2010. On September 22, 2014 the parties entered into an agreement settling this litigation. Under the settlement agreement, Par agreed not to initiate or assist in any future challenge to the validity or enforceability of the ‘882 patent and the ‘772 patent. Additionally, Par agreed that it will not sell or otherwise commercialize generic versions of Zegerid capsules or Zegerid powder during the term of the ‘882 patent and the ‘772 patent. As part of the settlement agreement, the parties have agreed, effective on the date of the filing of the Stipulation of Dismissal by Par, to release all claims asserted against one another in the this litigation or arising from Par’s sales of generic versions of Zegerid capsules or Zegerid powder; however, the Company, Santarus and the University of Missouri are not precluded from asserting the validity, enforceability or infringement of the ‘882 patent or the ‘772 patent in any future litigation concerning a generic version of a product other than Par’s generic version of Zegerid capsules. Par made a one-time payment of $100 million to an escrow account approved by Santarus and the University of Missouri, and these funds will be released and allocated between Santarus and the University of Missouri pursuant to terms of the Exclusive License Agreement between Santarus and the University of Missouri, dated January 26, 2001, as amended. A Stipulation of Dismissal was filed by Par on September 26, 2014, and entered by the Court on September 29, 2014.
	Fenoglide Patent Litigation
	In January 2013, Santarus filed a lawsuit in the U.S. District Court for the District of Delaware against Mylan Inc. and Mylan, collectively referred to herein as the Mylan parties, for infringement of the patents listed in the Orange Book for Fenoglide 120 mg and 40 mg (U.S. Patent Nos. 7,658,944, and 8,124,125). Veloxis Pharmaceuticals A/S, or Veloxis, is joined in the lawsuit as a co-plaintiff. The lawsuit was filed in response to an ANDA filed with the FDA by the Mylan parties regarding the Mylan parties’ intent to market a generic version of Fenoglide 120 mg and 40 mg tablets prior to the expiration of the listed patents. Santarus commenced the lawsuit within the requisite 45-day time period, resulting in an FDA stay on the approval of the Mylan parties’ proposed product for 30 months or until a decision is rendered by the District Court, which is adverse to the asserted patents, whichever may occur earlier. Absent a court decision, the 30-month stay is expected to expire in June 2015. The Mylan parties have filed an answer in the case that asserts, among other things, non-infringement, invalidity, and failure to state a claim, and it has also filed counterclaims. The court postponed at the request of the parties, and has not yet rescheduled, the pretrial evidentiary hearing, known as a Markman hearing. The Company is not able to predict the timing or outcome of this inquiry or its impact on financial conditions or results of operations.

Condensed_Consolidating_Financ

Condensed Consolidating Financial Information for Guarantors	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]
Condensed Consolidating Financial Information for Guarantors	19	Condensed Consolidating Financial Information for Guarantors
	The Guarantors currently guarantee the 2021 Notes, the Term Loan Facility and the Revolving Credit Facility. The guarantees are full and unconditional and joint and several, and each of the Guarantors is wholly owned, either directly or indirectly, by the Company. The Company has no independent assets or operations and all Company subsidiaries other than the Guarantors are minor, as such term is defined in Rule 3-10(h)(6) of Regulation S-X. As a result, the Company is not required to present condensed consolidating financial information for the Guarantors pursuant to Rule 3-10(f) of Regulation S-X.

Subsequent_Event

Subsequent Event	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]
Subsequent Event	20	Subsequent Event
	On July 8, 2014, the Company entered into an agreement and plan of merger and reorganization, or merger agreement, by and among the Company, Cosmo, Cosmo Tech, a subsidiary of Cosmo, and Sangiovese, LLC, or Merger Sub, a newly formed subsidiary of Cosmo Tech.
	On October 2, 2014, the Company entered into a termination agreement with Cosmo, Cosmo Tech, Merger Sub and Cosmo Holding S.p.A. wherein the parties mutually agreed to terminate, effective immediately upon execution of the termination agreement, the merger agreement. In consideration of the termination of the merger agreement, the Company paid Cosmo Tech $25 million, and the parties agreed to mutually release each other and certain related persons in respect of matters relating to the merger agreement and the transactions contemplated thereby.
	The foregoing descriptions of the termination agreement and merger agreement are not complete and are qualified in their entirety by the terms and conditions of the full text of the termination agreement, filed as an exhibit to Salix’s Current Report on Form 8-K filed on October 6, 2014, and the merger agreement, filed as an exhibit to Salix’s Current Report on Form 8-K filed on July 9, 2014, which are incorporated herein by reference.
	On February 22, 2015 the Company announced that it had entered into a definitive agreement with Valeant Pharmaceuticals International, Inc., under which Valeant will acquire all of the outstanding common stock of the Company. The acquisition is structured as an all-cash tender offer at a price of $158.00 per share followed by a merger in which each remaining untendered share of Salix common stock would be converted into the right to receive the same $158.00 cash per share consideration as in the tender offer. The transaction, which is expected to close in the second quarter of 2015, is subject to customary closing conditions and regulatory approval.

Restatement_of_Prior_Period_Fi1

Restatement of Prior Period Financial Statements (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Effect of Financial Statement Restatement Adjustments on Previously Reported Unaudited Condensed Consolidated Financial Statements	The following tables present the effect of financial statement restatement adjustments on our previously reported unaudited consolidated financial statements at September 30, 2014 and for the three and nine months then ended:
	Consolidated Balance Sheet
	(U.S. dollars, in thousands, except per share amounts)
		September 30, 2014									December 31, 2013
		(Unaudited)
		As			Error			Restated			As		Error			Restated
		previously			Correction						previously		Correction
		reported									reported
	ASSETS
	Current assets:
	Cash and cash equivalents	$	422,578		$	—		$	422,578		$	1,157,850	$	—		$	1,157,850
	Restricted cash		—			—			—			750,000		—			750,000
	Accounts receivable, net		522,632			(15,204	)		507,428			147,933		(14,352	)		133,581
	Inventory		155,150			(4,059	)		151,091			104,395		(186	)		104,209
	Deferred tax assets		223,011			(905	)		222,106			86,693		(905	)		85,788
	Prepaid expenses and other current assets		168,054			14,259			182,313			51,241		—			51,241
	Total current assets		1,491,425			(5,909	)		1,485,516			2,298,112		(15,443	)		2,282,669
	Property and equipment, net		34,382			—			34,382			27,312		—			27,312
	Goodwill		1,310,060			38,204			1,348,264			180,909		—			180,909
	Product rights and intangibles, net		1,912,405			(62,006	)		1,850,399			397,510		—			397,510
	Other assets		98,188			—			98,188			37,551		—			37,551
	Total assets	$	4,846,460		$	(29,711	)	$	4,816,749		$	2,941,394	$	(15,443	)	$	2,925,951
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities:
	Accounts payable	$	45,258		$	4,668		$	49,926		$	32,632	$	—		$	32,632
	Accrued liabilities		220,642			3,179			223,821			97,661		(752	)		96,909
	Income taxes payable		—			—			—			43,354		(8,534	)		34,820
	Reserve for product returns, rebates, chargebacks and patient-focused promotional programs		316,293			(2,656	)		313,637			246,838		5,991			252,829
	Current portion of convertible senior notes		911,263			—			911,263			—		—			—
	Current portion of Term Loan B credit facility		60,000			—			60,000			—		—			—
	Current portion of acquisition-related contingent consideration		40,000			—			40,000			—		—			—
	Current portion of capital lease obligations		16			—			16			47		—			47
	Total current liabilities		1,593,472			5,191			1,598,663			420,532		(3,295	)		417,237
	Long-term liabilities:
	Convertible senior notes		—			—			—			882,050		—			882,050
	Lease incentive obligation		9,233			—			9,233			8,610		—			8,610
	Term Loan B credit facility		1,095,000			—			1,095,000			—		—			—
	2021 senior notes		750,000			—			750,000			750,000		—			750,000
	Acquisition-related contingent consideration		165,037			—			165,037			87,300		—			87,300
	Deferred tax liabilities		567,014			(24,664	)		542,350			42,371		75			42,446
	Other long-term liabilities		15,041			—			15,041			9,665		—			9,665
	Total long-term liabilities		2,601,325			(24,664	)		2,576,661			1,779,996		75			1,780,071
	Unamortized debt discount due on conversion of senior notes		123,711			—			123,711			—		—			—
	Stockholders’ equity:
	Preferred stock, $0.001 par value; 5,000,000 shares authorized, issuable in series, none outstanding		—			—			—			—		—			—
	Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized, 63,718,571 and 62,937,966 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively		64			—			64			63		—			63
	Additional paid-in-capital		585,701			63			585,764			667,428		—			667,428
	Accumulated other comprehensive income/(loss)		(278	)		—			(278	)		1,721		—			1,721
	Retained earnings/(accumulated deficit)		(57,535	)		(10,301	)		(67,836	)		71,654		(12,223	)		59,431
	Total stockholders’ equity
			527,952			(10,238	)		517,714			740,866		(12,223	)		728,643
	Total liabilities and stockholders’ equity
		$	4,846,460		$	(29,711	)	$	4,816,749		$	2,941,394	$	(15,443	)	$	2,925,951
	Consolidated Statement of Comprehensive Income (Loss)
	(U.S. dollars, in thousands, except per share data)
		Nine Months Ended September 30, 2014
		(unaudited)
		As			Error			As Restated
		previously			Correction
		reported
	Revenues:
	Net product revenues	$	1,121,093		$	(1,027	)	$	1,120,066
	Costs and expenses:
	Cost of products sold (excluding amortization of product rights and intangibles of $161,849 for the nine-month period ended September 30, 2014.)		306,189			1,429			307,618
Amortization of product rights and intangible assets		164,843			(2,994	)		161,849
Change in acquisition-related contingent consideration		90,737			—			90,737
Research and development		142,826			(39,350	)		103,476
Selling, general and administrative		485,764			37,278			523,042
Total cost and expenses		1,190,359			(3,637	)		1,186,722
Income (loss) from operations		(69,266	)		2,610			(66,656	)
Interest expense		(128,525	)		375			(128,150	)
Interest income and other income (expense)		(1,451	)		—			(1,451	)
Income (loss) before provision for income tax		(199,242	)		2,985			(196,257	)
Income tax (expense) benefit		70,053			(1,063	)		68,990
Net income (loss)	$	(129,189	)	$	1,922		$	(127,267	)
Net income (loss) per share, basic	$	(2.04	)	$	0.03		$	(2.00	)
Net income (loss) per share, diluted	$	(2.04	)	$	0.03		$	(2.00	)
Shares used in computing net income (loss) per share, basic		63,482			—			63,482
Shares used in computing net income (loss) per share, diluted		63,482			—			63,482
Comprehensive income (loss)	$	(131,187	)	$	1,922		$	(129,265	)
	Three Months Ended September 30, 2014
	(unaudited)
	As			Error			As Restated
	previously			Correction
	reported
Revenues:
Net product revenues	$	354,719		$	(13,172	)	$	341,547
Costs and expenses:
Cost of products sold (excluding amortization of product rights and intangibles of $54,042 the three-month period ended September 30, 2014.)		86,298			(187	)		86,111
Amortization of product rights and intangible assets		55,040			(998	)		54,042
Change in acquisition-related contingent consideration		76,549			—			76,549
Research and development		50,837			(14,159	)		36,678
Selling, general and administrative		165,622			11,960			177,582
Total cost and expenses		434,346			(3,384	)		430,962
Income (loss) from operations		(79,627	)		(9,788	)		(89,415	)
Interest expense		(43,623	)		625			(42,998	)
Interest income and other income (expense)		(1,737	)		—			(1,737	)
Income (loss) before provision for income tax		(124,987	)		(9,163	)		(134,150	)
Income tax (expense) benefit		36,392			4,650			41,042
Net income (loss)	$	(88,595	)	$	(4,513	)	$	(93,108	)
Net income (loss) per share, basic	$	(1.39	)	$	(0.07	)	$	(1.46	)
Net income (loss) per share, diluted	$	(1.39	)	$	(0.07	)	$	(1.46	)
Shares used in computing net income (loss) per share, basic		63,687			—			63,687
Shares used in computing net income (loss) per share, diluted		63,687			—			63,687
Comprehensive income (loss)	$	(90,385	)	$	(4,513	)	$	(94,898	)
Consolidated Statement of Cash Flows
(U.S. dollars, in thousands, except per share amounts)
	Nine Months Ended September 30, 2014
	(unaudited)
	As previously			Error			As Restated
	reported			Correction
Cash Flows from Operating Activities
Net income (loss)	$	(129,189	)	$	1,922		$	(127,267	)
Adjustments to reconcile net income (loss) to net cash (used) provided by operating activities:					—			—
Depreciation and amortization		171,659			(2,994	)		168,665
Amortization of debt discount		29,239			—			29,239
Loss on disposal of property and equipment		555			—			555
Stock-based compensation expense		27,591			—			27,591
Change in acquisition-related contingent consideration		90,737			—			90,737
Changes in operating assets and liabilities:
Accounts receivable, inventory, prepaid expenses and other assets		(427,380	)		(7,478	)		(434,858	)
Accounts payable, accrued and other liabilities		60,863			17,134			77,997
Reserve for product returns, rebates, chargebacks and patient-focused promotional programs		28,563			(8,647	)		19,916
Net cash (used) provided by operating activities		(147,362	)		(63	)		(147,425	)
Cash Flows from Investing Activities
Business acquisitions, net of cash and cash equivalents acquired		(2,472,203	)		—			(2,472,203	)
Sale of short-term investments		44,867			—			44,867
Purchases of property and equipment		(13,376	)		—			(13,376	)
Net cash used by investing activities		(2,440,712	)		—			(2,440,712	)
Cash Flows from Financing Activities
Proceeds from senior notes		750,000			—			750,000
Proceeds from Term Loan B credit facility		1,200,000			—			1,200,000
Debt issuance costs		(65,839	)		—			(65,839	)
Principal payments on Term Loan B credit facility		(45,000	)		—			(45,000	)
Extinguishment of 2015 convertible senior notes		(26	)		—			(26	)
Excess tax benefit from stock-based compensation		16,151			63			16,214
Payments related to net settlement of stock-based awards		(7,329	)		—			(7,329	)
Proceeds from issuance of common stock upon exercise of stock options		5,572			—			5,572
Net cash provided (used) by financing activities		1,853,529			63			1,853,592
Effect of exchange rate changes on cash		(727	)		—			(727	)
Net (decrease) increase in cash and cash equivalents		(735,272	)		—			(735,272	)
Cash and cash equivalents at beginning of period		1,157,850			—			1,157,850
Cash and cash equivalents at end of period	$	422,578		$	—		$	422,578
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes	$	57,071		$	—		$	57,071
Cash paid for interest	$	78,326		$	—		$	78,326

Business_Combination_Tables

Business Combination (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]
Fair Values of Assets Acquired and Liabilities Assumed at Date of Acquisition	The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition:
	($ in thousands and unaudited)	January 2, 2014
		(Restated)
	Total consideration	$	2,671,212
	Tangible assets acquired and liabilities assumed:
	Cash and cash equivalents		171,259
	Restricted cash		750
	Investments		44,867
	Account receivables, net		50,634
	Inventory		49,498
	Current deferred tax assets		146,670
	Prepaid expenses and other current assets		7,353
	Property and equipment, net		1,064
	Other assets acquired		731
	Accounts payable		(11,142	)
	Accrued expenses		(20,203	)
	Reserve for product returns, rebates and chargebacks		(40,892	)
	Long-term deferred tax liability		(509,801	)
	Other long-term liabilities		(3,762	)
	Total tangible assets acquired and liabilities assumed		(112,974	)
	Intangible assets acquired:
	Currently marketed products (CMPs)		1,489,000
	In-process research & development products (IPR&D)		83,000
	Contractual agreements		44,000
	Total intangible assets acquired		1,616,000
	Total tangible and intangible assets acquired and liabilities assumed		1,503,026
	Goodwill	$	1,168,186
Unaudited Pro Forma Financial Information	Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date.
	($ in thousands)	Three Month			Nine Month
		Period Ended			Period Ended
		September 30,			September 30,
		2013			2013
	Revenue	$	336,978		$	943,822
	Net income		36,425			49,675
	Basic income per share		0.59			0.81
	Diluted income per share		0.55			0.76
Fair Value Adjustment for Purchase Accounting for Merger
	($ in thousands)	Weighted			Estimated		Amortization			Amortization
		Average			Fair Value		Expense for the			Expense for the
		Useful Life			As of		Three Month Period			Nine Month Period
		(years)			Acquisition		Ended			Ended
					Date		September 30, 2013			September 30,
										2013
	IPR&D		N/A			83,000		—			—
	Product rights on CMPs		15.4			1,489,000		41,657			124,996
	Licensing agreements		10			44,000		1,100			3,300
	Total pro forma amortization expense							42,757			128,296
	Less: historical amortization expense							(1,627	)		(4,752	)
	Net adjustment							41,130			123,544
Schedule of Notes and Borrowings Under Term Loan Facility
	($ in thousands)	Three Month			Nine Month
		Period Ended			Period Ended
		September 30,			September 30,
		2013			2013
	Interest on Term Loan B Facility of $1.2 billion and $750 million of 2021 Notes at an assumed weighted average cash interest rate of approximately 4.92%		24,000			72,000
	Amortization of debt issue costs and original issue discount		2,451			7,265
	Total adjustment		26,451			79,265

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Components of All Specifically Identifiable Intangible Assets	The following table reflects the components of all specifically identifiable intangible assets as of September 30, 2014 and December 31, 2013 (in thousands):
		September 30, 2014										December 31, 2013
		(Restated)
		Gross		Accumulated			Foreign			Net		Gross		Accumulated			Foreign		Net
		Amount		Amortization			Exchange			Carrying		Amount		Amortization			Exchange		Carrying
							Translation			Value							Translation		Value
	Goodwill	$	1,348,273	$	—		$	(9	)	$	1,348,264	$	180,905	$	—		$	4	$	180,909
	Finite lived intangible assets		2,056,367		(311,175	)		(393	)		1,744,799		490,367		(149,322	)		865		341,910
	Indefinite lived intangible assets		105,600		—			—			105,600		55,600		—			—		55,600
	Total	$	3,510,240	$	(311,175	)	$	(402	)	$	3,198,663	$	726,872	$	(149,322	)	$	869	$	578,419

Notes_Tables

Notes (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
Summary of Information on Convertible Senior Notes	The following table summarizes information on the convertible senior notes as of (in thousands):
		September 30,			December 31,
		2014			2013
	Convertible Senior Notes due 2015:
	Principal amount of the liability component	$	344,974		$	345,000
	Unamortized discount		(13,009	)		(26,356	)
	Net carrying amount	$	331,965		$	318,644
	Convertible Senior Notes due 2019:
	Principal amount of the liability component	$	690,000		$	690,000
	Unamortized discount		(110,702	)		(126,594	)
	Net carrying amount	$	579,298		$	563,406
	Total Convertible Senior Notes
	Principal amount of the liability component	$	1,034,974		$	1,035,000
	Unamortized discount		(123,711	)		(152,950	)
	Net carrying amount	$	911,263		$	882,050

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]
Summary of Activity in Additional Paid-In-Capital	The following table summarizes the activity in additional paid-in-capital for the nine-month periods ended September 30 (in thousands):
		2014			2013
		(Restated)
	Balance at December 31	$	667,428		$	631,364
	Issuance of common stock upon exercise of stock options		5,572			3,470
	Payments related to net settlement of stock-based awards		(7,329	)		(4,037	)
	Excess tax benefit from stock-based compensation		16,214			8,287
	Compensation expense related to restricted stock awards		27,590			18,832
	Reclassification of unamortized debt discount due on conversion of senior notes		(123,711	)		—
	Balance at September 30	$	585,764		$	657,916
Aggregate Stock Plan Activity	Aggregate stock plan activity is as follows:
		Total Shares			Stock Options					Restricted Shares					Stock Options and
		Available													Restricted Shares
		For Grant			Number			Weighted		Number			Weighted		Number			Weighted
								Average		Subject to			Average					Average
								Price		Issuance			Price					Price
	Balance at December 31, 2013		3,031,539			498,493		$	18.23		1,472,255		$	46.91		1,970,748		$	39.66
	Granted		(963,071	)		—					963,071		$	125.27		963,071		$	125.27
	Exercised		—			(299,816	)		18.58		—			—		(299,816	)	$	18.58
	Vested		—			—			—		(480,537	)	$	37.56		(480,537	)	$	37.56
	Additional shares authorized		1,500,000			—			—		—			—		—			—
	Canceled		125,612			(4,517	)		23.87		(121,095	)	$	87.1		(125,612	)	$	84.83
	Balance at September 30, 2014		3,694,080			194,160		$	17.56		1,833,694		$	87.86		2,027,854		$	81.13
Summary of Stock-Based Compensation Expense Incurred	The following table summarizes stock-based compensation expense incurred (in thousands):
		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014		2013
		(Restated)						(Restated)
	Research and development (as revised)	$	2,532		$	954		$	6,287	$	2,532
	Selling, general and administrative (as revised)		8,622			5,867			21,304		16,310
	Total	$	11,154		$	6,821		$	27,591	$	18,842

Net_Income_Loss_per_Share_Tabl

Net Income (Loss) per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator Used to Calculate Diluted Net Income (Loss) Per Share	The following table reconciles the numerator and denominator used to calculate diluted net income (loss) per share (in thousands):
		Three months ended					Nine months ended
		September 30,					September 30,
		2014			2013		2014			2013
		(Restated)					(Restated)
	Numerator:
	Net income (loss)	$	(93,108	)	$	47,331	$	(127,267	)	$	90,772
	Denominator:
	Weighted average common shares, basic		63,687			61,763		63,482			61,416
	Dilutive effect of restricted stock		—			675		—			552
	Dilutive effect of convertible debt		—			3,984		—			2,625
	Dilutive effect of stock options		—			407		—			438
	Weighted average common shares, diluted		63,687			66,829		63,482			65,031

Segment_Reporting_Tables

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]
Net Product Revenues by Product Category	The following table presents net product revenues by product category (in thousands):
		Three months ended					Nine months ended
		September 30,					September 30,
		2014			2013		2014		2013
		(Restated)					(Restated)
	Xifaxan	$	155,815		$	165,927	$	412,740	$	469,799
	Inflammatory Bowel Disease – Apriso/Uceris/Giazo/Colazal		73,126			38,321		220,199		101,927
	Diabetes – Glumetza and Cycloset		65,470			—		316,102		—
	Purgatives – OsmoPrep/MoviPrep		(1,263	)		19,232		15,404		54,108
	Zegerid		26,546			—		91,303		—
	Other – Fenoglide/Anusol/Azasan/Diuril/Pepcid/Proctocort/ Relistor/Deflux/Solesta/Fulyzaq/Metozolv		21,853			14,704		64,318		50,392
	Net product revenues	$	341,547		$	238,184	$	1,120,066	$	676,226

Restatement_of_Prior_Period_Fi2

Restatement of Prior Period Financial Statements - Summary of Financial Statement Restatement Adjustment on Balance Sheet (Detail) (USD $)	Sep. 30, 2014	Jan. 02, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$422,578		$1,157,850	$817,725	$751,006
Restricted cash			750,000
Accounts receivable, net	507,428		133,581
Inventory	151,091		104,209
Deferred tax assets	222,106		85,788
Prepaid expenses and other current assets	182,313		51,241
Total current assets	1,485,516		2,282,669
Property and equipment, net	34,382		27,312
Goodwill	1,348,264	1,168,186	180,909
Product rights and intangibles, net	1,850,399		397,510
Other assets	98,188		37,551
Total assets	4,816,749		2,925,951
Current liabilities:
Accounts payable	49,926		32,632
Accrued liabilities	223,821		96,909
Income taxes payable			34,820
Reserve for product returns, rebates, chargebacks and patient-focused promotional programs	313,637		252,829
Current portion of convertible senior notes	911,263
Current portion of capital lease obligations	16		47
Total current liabilities	1,598,663		417,237
Long-term liabilities:
Convertible senior notes			882,050
Lease incentive obligation	9,233		8,610
Acquisition-related contingent consideration	165,037		87,300
Deferred tax liabilities	542,350		42,446
Other long-term liabilities	15,041		9,665
Total long-term liabilities	2,576,661		1,780,071
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, issuable in series, none outstanding
Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized, 63,718,571 and 62,937,966 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	64		63
Additional paid-in-capital	585,764		667,428
Accumulated other comprehensive income/(loss)	-278		1,721
Retained earnings/(accumulated deficit)	-67,836		59,431
Total stockholders' equity	517,714		728,643
Total liabilities and stockholders' equity	4,816,749		2,925,951
Term Loan B Facility [Member]
Current liabilities:
Current portion of Term Loan B credit facility	60,000
Current portion of acquisition-related contingent consideration	40,000
Long-term liabilities:
Term Loan B credit facility	1,095,000
6.60% Senior Notes Due 2021 [Member]
Long-term liabilities:
2021 senior notes	750,000		750,000
Convertible Senior Notes
Long-term liabilities:
Convertible senior notes	911,263		882,050
Unamortized debt discount due on conversion of senior notes	123,711		152,950
As Previously Reported [Member]
Current assets:
Cash and cash equivalents	422,578		1,157,850
Restricted cash			750,000
Accounts receivable, net	522,632		147,933
Inventory	155,150		104,395
Deferred tax assets	223,011		86,693
Prepaid expenses and other current assets	168,054		51,241
Total current assets	1,491,425		2,298,112
Property and equipment, net	34,382		27,312
Goodwill	1,310,060		180,909
Product rights and intangibles, net	1,912,405		397,510
Other assets	98,188		37,551
Total assets	4,846,460		2,941,394
Current liabilities:
Accounts payable	45,258		32,632
Accrued liabilities	220,642		97,661
Income taxes payable			43,354
Reserve for product returns, rebates, chargebacks and patient-focused promotional programs	316,293		246,838
Current portion of convertible senior notes	911,263
Current portion of capital lease obligations	16		47
Total current liabilities	1,593,472		420,532
Long-term liabilities:
Convertible senior notes			882,050
Lease incentive obligation	9,233		8,610
Acquisition-related contingent consideration	165,037		87,300
Deferred tax liabilities	567,014		42,371
Other long-term liabilities	15,041		9,665
Total long-term liabilities	2,601,325		1,779,996
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, issuable in series, none outstanding
Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized, 63,718,571 and 62,937,966 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	64		63
Additional paid-in-capital	585,701		667,428
Accumulated other comprehensive income/(loss)	-278		1,721
Retained earnings/(accumulated deficit)	-57,535		71,654
Total stockholders' equity	527,952		740,866
Total liabilities and stockholders' equity	4,846,460		2,941,394
As Previously Reported [Member] | Term Loan B Facility [Member]
Current liabilities:
Current portion of Term Loan B credit facility	60,000
Current portion of acquisition-related contingent consideration	40,000
Long-term liabilities:
Term Loan B credit facility	1,095,000
As Previously Reported [Member] | 6.60% Senior Notes Due 2021 [Member]
Long-term liabilities:
2021 senior notes	750,000		750,000
As Previously Reported [Member] | Convertible Senior Notes
Long-term liabilities:
Unamortized debt discount due on conversion of senior notes	123,711
Error Correction [Member]
Current assets:
Accounts receivable, net	-15,204		-14,352
Inventory	-4,059		-186
Deferred tax assets	-905		-905
Prepaid expenses and other current assets	14,259
Total current assets	-5,909		-15,443
Goodwill	38,204
Product rights and intangibles, net	-62,006
Total assets	-29,711		-15,443
Current liabilities:
Accounts payable	4,668
Accrued liabilities	3,179		-752
Income taxes payable			-8,534
Reserve for product returns, rebates, chargebacks and patient-focused promotional programs	-2,656		5,991
Total current liabilities	5,191		-3,295
Long-term liabilities:
Deferred tax liabilities	-24,664		75
Total long-term liabilities	-24,664		75
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, issuable in series, none outstanding
Additional paid-in-capital	63
Retained earnings/(accumulated deficit)	-10,301		-12,223
Total stockholders' equity	-10,238		-12,223
Total liabilities and stockholders' equity	($29,711)		($15,443)

Restatement_of_Prior_Period_Fi3

Restatement of Prior Period Financial Statements - Summary of Financial Statement Restatement Adjustment on Balance Sheet (Parenthetical) (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	150,000,000
Common stock, shares issued	63,718,571	62,937,966
Common stock, shares outstanding	63,718,571	62,937,966
As Previously Reported [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	150,000,000
Common stock, shares issued	63,718,571	62,937,966
Common stock, shares outstanding	63,718,571	62,937,966
Error Correction [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	150,000,000
Common stock, shares issued	63,718,571	62,937,966
Common stock, shares outstanding	63,718,571	62,937,966

Restatement_of_Prior_Period_Fi4

Restatement of Prior Period Financial Statements - Summary of Financial Statement Restatement Adjustment on Comprehensive Income (Loss) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:
Net product revenues	$341,547	$238,184	$1,120,066	$676,226
Costs and expenses:
Cost of products sold (excluding amortization of product rights and intangibles of $161,849 for the nine-month period ended September 30, 2014.)	86,111	42,899	307,618	122,460
Amortization of product rights and intangible assets	54,042	11,189	161,849	33,518
Change in acquisition-related contingent consideration	76,549	2,400	90,737	7,000
Research and development	36,678	29,180	103,476	85,891
Selling, general and administrative	177,582	76,202	523,042	251,627
Total cost and expenses	430,962	161,870	1,186,722	500,496
Income (loss) from operations	-89,415	76,314	-66,656	175,730
Interest expense	-42,998	-15,497	-128,150	-46,285
Interest income and other income (expense)	-1,737	712	-1,451	1,348
Income (loss) before provision for income tax	-134,150	61,529	-196,257	130,793
Income tax (expense) benefit	41,042	-14,198	68,990	-40,021
Net income (loss)	-93,108	47,331	-127,267	90,772
Net income (loss) per share, basic	($1.46)	$0.77	($2)	$1.48
Net income (loss) per share, diluted	($1.46)	$0.71	($2)	$1.40
Shares used in computing net income (loss) per share, basic	63,687	61,763	63,482	61,416
Shares used in computing net income (loss) per share, diluted	63,687	66,829	63,482	65,031
Comprehensive income (loss)	-94,898	48,511	-129,265	91,427
As Previously Reported [Member]
Revenues:
Net product revenues	354,719		1,121,093
Costs and expenses:
Cost of products sold (excluding amortization of product rights and intangibles of $161,849 for the nine-month period ended September 30, 2014.)	86,298		306,189
Amortization of product rights and intangible assets	55,040		164,843
Change in acquisition-related contingent consideration	76,549		90,737
Research and development	50,837		142,826
Selling, general and administrative	165,622		485,764
Total cost and expenses	434,346		1,190,359
Income (loss) from operations	-79,627		-69,266
Interest expense	-43,623		-128,525
Interest income and other income (expense)	-1,737		-1,451
Income (loss) before provision for income tax	-124,987		-199,242
Income tax (expense) benefit	36,392		70,053
Net income (loss)	-88,595		-129,189
Net income (loss) per share, basic	($1.39)		($2.04)
Net income (loss) per share, diluted	($1.39)		($2.04)
Shares used in computing net income (loss) per share, basic	63,687		63,482
Shares used in computing net income (loss) per share, diluted	63,687		63,482
Comprehensive income (loss)	-90,385		-131,187
Error Correction [Member]
Revenues:
Net product revenues	-13,172		-1,027
Costs and expenses:
Cost of products sold (excluding amortization of product rights and intangibles of $161,849 for the nine-month period ended September 30, 2014.)	-187		1,429
Amortization of product rights and intangible assets	-998		-2,994
Research and development	-14,159		-39,350
Selling, general and administrative	11,960		37,278
Total cost and expenses	-3,384		-3,637
Income (loss) from operations	-9,788		2,610
Interest expense	625		375
Income (loss) before provision for income tax	-9,163		2,985
Income tax (expense) benefit	4,650		-1,063
Net income (loss)	-4,513		1,922
Net income (loss) per share, basic	($0.07)		$0.03
Net income (loss) per share, diluted	($0.07)		$0.03
Comprehensive income (loss)	($4,513)		$1,922

Restatement_of_Prior_Period_Fi5

Restatement of Prior Period Financial Statements - Summary of Financial Statement Restatement Adjustment on Comprehensive Income (Loss) (Parenthetical) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Amortization of product rights and intangible assets	$54,042	$11,189	$161,849	$33,518
As Previously Reported [Member]
Amortization of product rights and intangible assets	55,040		164,843
Error Correction [Member]
Amortization of product rights and intangible assets	($998)		($2,994)

Restatement_of_Prior_Period_Fi6

Restatement of Prior Period Financial Statements - Summary of Financial Statement Restatement Adjustment on Cash Flows (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities
Net(loss)income	($127,267)	$90,772
Adjustments to reconcile net income (loss) to net cash (used) provided by operating activities:
Depreciation and amortization	168,665	38,965
Amortization of debt discount	29,239	27,933
Loss on disposal of property and equipment	555	113
Stock-based compensation expense	27,591	18,832
Change in acquisition-related contingent consideration	90,737	7,000
Changes in operating assets and liabilities:
Accounts receivable, inventory, prepaid expenses and other assets	-434,858	-168,361
Accounts payable, accrued and other liabilities	77,997	-3,744
Reserve for product returns, rebates, chargebacks and patient-focused promotional programs	19,916	63,849
Net cash (used) provided by operating activities	-147,425	75,359
Cash flows from investing activities
Business acquisition, net of cash and cash equivalents acquired	-2,472,203
Sale of short-term investments	44,867
Purchases of property and equipment	-13,376	-4,114
Net cash used in investing activities	-2,440,712	-4,114
Cash flows from financing activities
Debt issuance costs	-65,839
Extinguishment of 2015 convertible senior notes	-26	-12,500
Excess tax benefit from stock-based compensation	16,214	8,287
Payments related to net settlement of stock-based awards	-7,329	-4,037
Proceeds from issuance of common stock upon exercise of stock options	5,572	3,472
Net cash (used) provided by financing activities	1,853,592	-4,778
Effect of exchange rate changes on cash	-727	252
Net (decrease) increase in cash and cash equivalents	-735,272	66,719
Cash and cash equivalents at beginning of period	1,157,850	751,006
Cash and cash equivalents at end of period	422,578	817,725
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes	57,071	62,049
Cash paid for interest	78,326	15,781
6.60% Senior Notes Due 2021 [Member]
Cash flows from financing activities
Proceeds from senior notes	750,000
Term Loan B Facility [Member]
Cash flows from financing activities
Proceeds from Term Loan B credit facility	1,200,000
Principal payments on Term Loan B credit facility	-45,000
As Previously Reported [Member]
Cash flows from operating activities
Net(loss)income	-129,189
Adjustments to reconcile net income (loss) to net cash (used) provided by operating activities:
Depreciation and amortization	171,659
Amortization of debt discount	29,239
Loss on disposal of property and equipment	555
Stock-based compensation expense	27,591
Change in acquisition-related contingent consideration	90,737
Changes in operating assets and liabilities:
Accounts receivable, inventory, prepaid expenses and other assets	-427,380
Accounts payable, accrued and other liabilities	60,863
Reserve for product returns, rebates, chargebacks and patient-focused promotional programs	28,563
Net cash (used) provided by operating activities	-147,362
Cash flows from investing activities
Business acquisition, net of cash and cash equivalents acquired	-2,472,203
Sale of short-term investments	44,867
Purchases of property and equipment	-13,376
Net cash used in investing activities	-2,440,712
Cash flows from financing activities
Debt issuance costs	-65,839
Extinguishment of 2015 convertible senior notes	-26
Excess tax benefit from stock-based compensation	16,151
Payments related to net settlement of stock-based awards	-7,329
Proceeds from issuance of common stock upon exercise of stock options	5,572
Net cash (used) provided by financing activities	1,853,529
Effect of exchange rate changes on cash	-727
Net (decrease) increase in cash and cash equivalents	-735,272
Cash and cash equivalents at beginning of period	1,157,850
Cash and cash equivalents at end of period	422,578
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes	57,071
Cash paid for interest	78,326
As Previously Reported [Member] | 6.60% Senior Notes Due 2021 [Member]
Cash flows from financing activities
Proceeds from senior notes	750,000
As Previously Reported [Member] | Term Loan B Facility [Member]
Cash flows from financing activities
Proceeds from Term Loan B credit facility	1,200,000
Principal payments on Term Loan B credit facility	-45,000
Error Correction [Member]
Cash flows from operating activities
Net(loss)income	1,922
Adjustments to reconcile net income (loss) to net cash (used) provided by operating activities:
Depreciation and amortization	-2,994
Changes in operating assets and liabilities:
Accounts receivable, inventory, prepaid expenses and other assets	-7,478
Accounts payable, accrued and other liabilities	17,134
Reserve for product returns, rebates, chargebacks and patient-focused promotional programs	-8,647
Net cash (used) provided by operating activities	-63
Cash flows from financing activities
Excess tax benefit from stock-based compensation	63
Net cash (used) provided by financing activities	$63

Business_Combination_Additiona

Business Combination - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jan. 02, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Common stock, par value	$0.00		$0.00			$0.00
Preferred stock, par value	$0.00		$0.00			$0.00
Business acquisition cash payment					$171,259,000
Interest rate	2.00%		2.00%
Maturity date			2-Jan-20
Acquisition-related contingent consideration					27,000,000
Fair value of inventory acquired	37,300,000		37,300,000
Proceed from sale of inventory acquired	2,500,000		37,200,000
Intangible assets estimated weighted average useful life			15 years 4 months 24 days
Deferred tax assets	146,700,000		146,700,000
Deferred tax liability	509,800,000		509,800,000
Net Revenues		336,978,000		943,822,000
Operating Income		36,425,000		49,675,000
Business Acquisition transaction cost	126,800,000		126,800,000
Incremental amortization expense		41,100,000		123,500,000
Incremental interest expense		26,500,000		79,300,000
Combined federal and state statutory income tax rate				39.00%
Senior Notes [Member]
Business Acquisition [Line Items]
Debt instrument, face amount		750,000,000		750,000,000
Pro Forma [Member]
Business Acquisition [Line Items]
Non-recurring transaction expense				65,500,000
Pro Forma [Member] | Senior Notes [Member]
Business Acquisition [Line Items]
Debt instrument, face amount		750,000,000		750,000,000
Term Loan B Facility [Member]
Business Acquisition [Line Items]
Debt instrument, face amount		1,200,000,000		1,200,000,000
Santarus, Inc.
Business Acquisition [Line Items]
Common stock, par value					$0.00
Preferred stock, par value					$0.00
Business acquisition purchase price per share					$32
Payment of acquisition					2,700,000,000
Business acquisition cash payment					848,100,000
Interest rate					6.00%
Net Revenues	134,600,000		565,600,000
Operating Income	16,300,000		138,000,000
Santarus, Inc. | Term Loan B Facility [Member]
Business Acquisition [Line Items]
Borrowings on term loan facility					1,200,000,000
Santarus, Inc. | 6.60% Senior Notes Due 2021 [Member]
Business Acquisition [Line Items]
Proceed from senior notes					750,000,000
Maturity date			15-Jan-21
Selling, General and Administrative Expenses
Business Acquisition [Line Items]
Business Acquisition transaction cost	65,500,000		65,500,000
Debt Issuance Costs [Member]
Business Acquisition [Line Items]
Business Acquisition transaction cost	$61,300,000		$61,300,000
Product Rights on CMPs [Member] | Pro Forma [Member]
Business Acquisition [Line Items]
Intangible assets estimated weighted average useful life				15 years 4 months 24 days
Product Rights on CMPs [Member] | Minimum
Business Acquisition [Line Items]
Discount rate used to arrive present value			9.00%
Product Rights on CMPs [Member] | Maximum
Business Acquisition [Line Items]
Discount rate used to arrive present value			9.50%
In Process Research and Development Products [Member] | Minimum
Business Acquisition [Line Items]
Discount rate used to arrive present value			10.00%
In Process Research and Development Products [Member] | Maximum
Business Acquisition [Line Items]
Discount rate used to arrive present value			11.00%

Business_Combination_Fair_Valu

Business Combination - Fair Values of Assets Acquired and Liabilities Assumed at Date of Acquisition (Detail) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2014	Sep. 30, 2014	Jan. 02, 2014	Dec. 31, 2013
Business Combinations [Abstract]
Total consideration	$2,671,212
Cash and cash equivalents			171,259
Restricted cash			750
Investments			44,867
Account receivables, net			50,634
Inventory			49,498
Current deferred tax assets			146,670
Prepaid expenses and other current assets			7,353
Property and equipment, net			1,064
Other assets acquired			731
Accounts payable			-11,142
Accrued expenses			-20,203
Reserve for product returns, rebates and chargebacks			-40,892
Long-term deferred tax liability			-509,801
Other long-term liabilities			-3,762
Total tangible assets acquired and liabilities assumed			-112,974
Currently marketed products (CMPs)			1,489,000
In-process research & development products (IPR&D)			83,000
Contractual agreements			44,000
Total intangible assets acquired			1,616,000
Total tangible and intangible assets acquired and liabilities assumed			1,503,026
Goodwill		$1,348,264	$1,168,186	$180,909

Business_Combination_Unaudited

Business Combination - Unaudited Pro Forma Financial Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Business Combinations [Abstract]
Revenue	$336,978	$943,822
Net income	$36,425	$49,675
Basic income per share	$0.59	$0.81
Diluted income per share	$0.55	$0.76

Business_Combination_Fair_Valu1

Business Combination - Fair Value Adjustment for Purchase Accounting for Merger (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (years)			15 years 4 months 24 days
Amortization Expense	$54,042	$11,189	$161,849	$33,518
Pro Forma [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization Expense		42,757		128,296
Pro Forma [Member] | In Process Research and Development Products [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated Fair Value As of Acquisition Date		83,000		83,000
Pro Forma [Member] | Product Rights on CMPs [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (years)				15 years 4 months 24 days
Estimated Fair Value As of Acquisition Date		1,489,000		1,489,000
Amortization Expense		41,657		124,996
Pro Forma [Member] | Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (years)				10 years
Estimated Fair Value As of Acquisition Date		44,000		44,000
Amortization Expense		1,100		3,300
Historical Amortization Expense [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization Expense		-1,627		-4,752
Adjustments [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization Expense		$41,130		$123,544

Business_Combination_Schedule_

Business Combination - Schedule of Notes and Borrowings Under Term Loan Facility (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Business Acquisition [Line Items]
Interest on Term Loan B Facility of $1.2 billion and $750 million of 2021 Notes at an assumed weighted average cash interest rate of approximately 4.92%	$42,998	$15,497	$128,150	$46,285
Pro Forma [Member]
Business Acquisition [Line Items]
Interest on Term Loan B Facility of $1.2 billion and $750 million of 2021 Notes at an assumed weighted average cash interest rate of approximately 4.92%		24,000		72,000
Amortization of debt issue costs and original issue discount		2,451		7,265
Total adjustment		$26,451		$79,265

Business_Combination_Schedule_1

Business Combination - Schedule of Notes and Borrowings Under Term Loan Facility (Parenthetical) (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Senior Notes [Member]
Business Acquisition [Line Items]
Debt instrument, face amount	$750,000
Pro Forma [Member]
Business Acquisition [Line Items]
Debt, weighted average interest rate	4.92%
Pro Forma [Member] | Term Loan B Facility [Member]
Business Acquisition [Line Items]
Debt instrument, face amount	1,200,000
Pro Forma [Member] | Senior Notes [Member]
Business Acquisition [Line Items]
Debt instrument, face amount	$750,000

Revenue_Recognition_Additional

Revenue Recognition - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Allowances for estimated rebates, chargebacks and patient focused promotional programs	257.4		257.4		$184.60
Allowances for product returns	56.2		56.2		$68.20
Rebates Chargebacks and Patient-focused Promotional Programs [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Provision for revenue-reducing items, as percentage of gross product revenue	24.30%	23.70%	19.60%	21.90%
Product Returns
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Provision for revenue-reducing items, as percentage of gross product revenue	2.80%	1.80%	0.40%	2.10%

Commitments_Additional_Informa

Commitments - Additional Information (Detail) (USD $)

9 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Sep. 30, 2014

Sep. 30, 2009

Mar. 31, 2011

Jul. 31, 2013

Sep. 30, 2010

Sep. 30, 2014

Nov. 30, 2012

Dec. 31, 2014

Aug. 31, 2012

Mar. 31, 2008

Dec. 31, 2008

Feb. 28, 2011

Oct. 31, 2014

Dec. 31, 2011

Nov. 30, 2013

Jan. 31, 2001

Feb. 28, 2014

Oct. 31, 2009

Dec. 31, 2005

Right

Long-term Purchase Commitment [Line Items]

Purchase order commitments for inventory purchases

$181,100,000

$181,100,000

Payment On Territory Expansion [Member]

Long-term Purchase Commitment [Line Items]

License fee payments

1,000,000

Lupin Ltd.

Long-term Purchase Commitment [Line Items]

License fee payments

10,000,000

Maximum milestone payments

5,000,000

License agreement expiry date

30-Sep-19

Lupin Ltd. | Amended and Restated Development, Commercialization and License Agreement

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

10,000,000

Lupin Ltd. | Maximum | Amended and Restated Development, Commercialization and License Agreement

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

53,000,000

Norgine B.V.

Long-term Purchase Commitment [Line Items]

License fee payments

27,000,000

Norgine B.V. | Maximum

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

37,000,000

Pharming Group NV [Member]

Long-term Purchase Commitment [Line Items]

License fee payments

20,000,000

Maximum milestone payments

15,000,000

20,000,000

Pharming Group NV [Member] | Successful Achievement Of Phase Three Clinical Study [Member]

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

10,000,000

Pharming Group NV [Member] | FDA Acceptance For Review Of Biologics License Application [Member]

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

5,000,000

Pharming Group NV [Member] | Commercial Milestone Payments [Member]

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

25,000,000

Pharming Group NV [Member] | Scenario, Forecast [Member]

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

20,000,000

Pharming Group NV [Member] | Maximum

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

45,000,000

Alfa Wassermann EIR

Long-term Purchase Commitment [Line Items]

License fee payments

0

10,000,000

Alfa Wassermann EIR | Receipt of Marketing Authorization

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

25,000,000

Alfa Wassermann EIR | Maximum | Net Sales of Rifaximin Products

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

200,000,000

Dr. Falk Pharma GmbH

Long-term Purchase Commitment [Line Items]

License fee payments

2,500,000

Dr. Falk Pharma GmbH | Budesonide Rectal Foam

Long-term Purchase Commitment [Line Items]

Patent expiration dates

2015

Dr. Falk Pharma GmbH | Budesonide Rectal Foam | Scenario, Forecast [Member]

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

7,000,000

Dr. Falk Pharma GmbH | Maximum

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

9,500,000

Napo Pharmaceuticals, Inc.

Long-term Purchase Commitment [Line Items]

License fee payments

5,000,000

Napo Pharmaceuticals, Inc. | HIV-Associated Diarrhea

Long-term Purchase Commitment [Line Items]

License fee payments

12,000,000

Development costs

12,000,000

Napo Pharmaceuticals, Inc. | Maximum | Napo Contingent on Regulatory Approvals

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

50,000,000

Napo Pharmaceuticals, Inc. | Maximum | Sales Thresholds

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

250,000,000

Progenics Pharmaceuticals, Inc.

Long-term Purchase Commitment [Line Items]

License fee payments

0

60,000,000

Progenics Pharmaceuticals, Inc. | Subsequent Event | Relistor Subcutaneous Injection [Member]

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

40,000,000

Progenics Pharmaceuticals, Inc. | Maximum | Development Milestone

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

90,000,000

Progenics Pharmaceuticals, Inc. | Maximum | Commercialization Milestone

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

200,000,000

Q-Med

Long-term Purchase Commitment [Line Items]

Number of license agreements acquired

2

Q-Med | Commercialization Milestone

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

0

Q-Med | Maximum | Commercialization Milestone

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

45,000,000

Cosmo Technologies Limited [Member]

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

22,500,000

Licensing and milestone payments

9,500,000

Cosmo Technologies Limited [Member] | Maximum

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

22,500,000

University Of Missouri [Member]

Long-term Purchase Commitment [Line Items]

Licensing and milestone payments

8,500,000

Additional milestone payments

7,500,000

University Of Missouri [Member] | Maximum

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

83,800,000

Milestone payments based on net product sales

250,000,000

Biogen Idec Inc [Member]

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

0

Biogen Idec Inc [Member] | San 300 [Member]

Long-term Purchase Commitment [Line Items]

License fee payments

105,500,000

Maximum milestone payments

97,200,000

Assumed cumulative net sales

5,000,000,000

Biogen Idec Inc [Member] | Other products [Member]

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

60,250,000

Red Hill Biopharma Ltd [Member]

Long-term Purchase Commitment [Line Items]

License fee payments

11,500,000

Maximum milestone payments

0

Red Hill Biopharma Ltd [Member] | Maximum | Development Milestone

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

12,500,000

Red Hill Biopharma Ltd [Member] | Maximum | Commercialization Milestone

Long-term Purchase Commitment [Line Items]

Maximum milestone payments

15,000,000

Cipla Ltd [Member]

Long-term Purchase Commitment [Line Items]

License fee payments

0

2,000,000

Maximum milestone payments

6,000,000

Cipla Ltd [Member] | Enumeration Patents of Rifaximin Complexes [Member]

Long-term Purchase Commitment [Line Items]

License fee payments

9,000,000

Maximum milestone payments

$20,000,000

Financial_Instruments_Recurrin1

Financial Instruments, Recurring and Nonrecurring Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Acquisition-related contingent consideration	$165,037,000	$165,037,000	$87,300,000
Change in fair value of contingent consideration liability	76,500,000	90,700,000
Oceana and Progenics Acquisitions | Fair Value, Inputs, Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Acquisition-related contingent consideration	$205,000,000	$205,000,000	$87,300,000

Cash_and_Cash_Equivalents_Addi

Cash and Cash Equivalents - Additional Information (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Cash and Cash Equivalents [Line Items]
Restricted cash		$750,000
Convertible notes maturity date	2-Jan-20
2021 Notes
Cash and Cash Equivalents [Line Items]
Convertible notes issuance date	27-Dec-13
Convertible notes maturity date	15-Jan-21
2021 Notes | Santarus, Inc.
Cash and Cash Equivalents [Line Items]
Convertible notes maturity date	2-Jan-14

Inventory_Additional_Informati

Inventory - Additional Information (Detail) (USD $)	Sep. 30, 2014	Jan. 02, 2014	Dec. 31, 2013
Inventory [Line Items]
Inventory, raw materials	$68,300,000		$61,000,000
Inventory, work-in-process	20,200,000		11,700,000
Inventory, finished goods	62,600,000		31,500,000
Inventory acquired in the acquisition of Santarus		49,498,000
Santarus, Inc.
Inventory [Line Items]
Inventory acquired in the acquisition of Santarus	$100,000

Intangible_Assets_and_Goodwill2

Intangible Assets and Goodwill - Components of All Specifically Identifiable Intangible Assets (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Jan. 02, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, Gross amount	$1,348,273	$180,905
Finite lived intangible assets, Gross amount	2,056,367	490,367
Indefinite lived intangible assets, Gross amount	105,600	55,600
Total, Gross amount	3,510,240	726,872
Finite lived intangible assets, Accumulated amortization	-311,175	-149,322
Total, Accumulated amortization	-311,175	-149,322
Goodwill, Foreign exchange translation	-9	4
Finite lived intangible assets, Foreign exchange translation	-393	865
Indefinite lived intangible assets, Foreign exchange translation	0	0
Total, Foreign exchange translation	-402	869
Goodwill, Net carrying value	1,348,264	180,909	1,168,186
Finite lived intangible assets, Net carrying value	1,744,799	341,910
Indefinite lived intangible assets, Net carrying value	105,600	55,600
Total, Net carrying value	$3,198,663	$578,419

Intangible_Assets_and_Goodwill3

Intangible Assets and Goodwill - Additional Information (Detail) (USD $)	3 Months Ended			9 Months Ended		12 Months Ended	0 Months Ended	1 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Jan. 02, 2014	Feb. 28, 2011	Dec. 31, 2011	Aug. 31, 2012
Goodwill And Intangible Assets [Line Items]
Acquired intangible assets amortization period, in years				14 years		8 years
Amortization Expense	$54,042,000	$11,189,000		$161,849,000	$33,518,000
Intangible asset impairment charge			41,600,000
Accumulated amortization of intangible assets	311,175,000			311,175,000		149,322,000
Intangible assets recorded	2,056,367,000			2,056,367,000		490,367,000
Carrying value of intangible assets	1,744,799,000			1,744,799,000		341,910,000
Relistor [Member]
Goodwill And Intangible Assets [Line Items]
Accumulated amortization of intangible assets	9,100,000			9,100,000		7,200,000
Santarus, Inc.
Goodwill And Intangible Assets [Line Items]
Acquired intangible assets amortization period, in years	10 years
Finite lived intangible assets acquired							1,533,000,000
Infinite lived intangible assets acquired							83,000,000
Goodwill acquired							1,168,200,000
Transfer of intangible assets from indefinite lived to finite lived	33,000,000
Acquisition purchase price							2,700,000,000
Progenics Pharmaceuticals, Inc.
Goodwill And Intangible Assets [Line Items]
Percentage of sublicensees revenue payable								60.00%
Milestone payments to acquire intangible assets								60,000,000
Net assets acquired								113,000,000
Progenics Pharmaceuticals, Inc. | Commercialization Milestone
Goodwill And Intangible Assets [Line Items]
Milestone payments to acquire intangible assets								200,000,000
Progenics Pharmaceuticals, Inc. | Development Milestone
Goodwill And Intangible Assets [Line Items]
Milestone payments to acquire intangible assets								90,000,000
Oceana Therapeutics, Inc.
Goodwill And Intangible Assets [Line Items]
Net assets acquired									342,800,000
Acquisition purchase price									303,000,000
Oceana Therapeutics, Inc. | Maximum
Goodwill And Intangible Assets [Line Items]
Milestone payments to acquire intangible assets									45,000,000
Oceana Therapeutics, Inc. | Deflux Intangible
Goodwill And Intangible Assets [Line Items]
Accumulated amortization of intangible assets	12,900,000			12,900,000		9,300,000
Oceana Therapeutics, Inc. | Solesta Intangible
Goodwill And Intangible Assets [Line Items]
Accumulated amortization of intangible assets	79,900,000			79,900,000		58,100,000
Alfa Wassermann EIR
Goodwill And Intangible Assets [Line Items]
Milestone payments to acquire intangible assets										10,000,000
Net assets acquired										23,400,000
Alfa Wassermann EIR | Receipt of Marketing Authorization
Goodwill And Intangible Assets [Line Items]
Milestone payments for purchase commitment										25,000,000
Alfa Wassermann EIR | Net Sales of Rifaximin Products | Maximum
Goodwill And Intangible Assets [Line Items]
Milestone payments for purchase commitment										200,000,000
Pharmaceutical Companies [Member]
Goodwill And Intangible Assets [Line Items]
Accumulated amortization of intangible assets	80,000,000			80,000,000		74,400,000
Intangible assets recorded	147,200,000			147,200,000
Carrying value of intangible assets	$32,800,000			$32,800,000		$38,200,000

Notes_Additional_Information_D

Notes - Additional Information (Detail) (USD $)	9 Months Ended		0 Months Ended	1 Months Ended	3 Months Ended		0 Months Ended	3 Months Ended		0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Aug. 22, 2008	Mar. 31, 2012	Dec. 31, 2012	Mar. 31, 2012	Jun. 03, 2010	Sep. 30, 2014	Sep. 30, 2013	Mar. 16, 2012	Dec. 27, 2013	Jan. 02, 2014	Dec. 31, 2013
Debt Conversion [Line Items]
Convertible senior notes, interest rate percentage	2.00%							2.00%
Convertible notes maturity date	2-Jan-20
Debt issuance costs	$65,839,000
Amortization of debt discount	29,239,000	27,933,000
Santarus, Inc.
Debt Conversion [Line Items]
Purchase price per share												$32
Convertible Senior Notes Due 2028
Debt Conversion [Line Items]
Convertible Senior Notes, par value	12,500,000		60,000,000					12,500,000
Net proceeds from offering			57,300,000
Convertible notes issuance date	22-Aug-08
Convertible senior notes, interest rate percentage	5.50%							5.50%
Convertible senior notes, frequency of periodic payment	Payable semiannually in arrears on February 15 and August 15 of each year
Convertible notes maturity date	15-Aug-28
Percentage of notes purchased				42.10%
Convertible senior notes aggregate purchase price				137,200,000	22,300,000	137,200,000
Loss on extinguishment of debt					1,200,000	14,400,000
Estimated fair market value of put option granted to majority holder						9,300,000
Estimated fair market value of notes extinguished over their book value					1,100,000	2,500,000
Interest paid to note holder					100,000	2,000,000
Issuance of common stock upon conversion of 2028 Notes	1,200,000				1,900,000
Debt issuance costs	2,700,000
Effective interest rate on convertible note	12.50%							12.50%
Initial fair value of liability component due to convertible debt	44,100,000							44,100,000
Proceeds from convertible senior notes in excess of initial liability component	15,900,000
Price per share for conversion of debt	$9.25							$9.25
Convertible Senior Notes Due 2015
Debt Conversion [Line Items]
Convertible Senior Notes, par value	344,974,000						345,000,000	344,974,000					345,000,000
Net proceeds from offering							334,200,000
Convertible notes issuance date	3-Jun-10
Convertible senior notes, interest rate percentage	2.75%							2.75%
Convertible senior notes, frequency of periodic payment	Payable semiannually in arrears on May 15 and November 15 of each year
Convertible notes maturity date	15-May-15
Debt issuance costs	10,800,000
Effective interest rate on convertible note	8.35%							8.35%
Initial fair value of liability component due to convertible debt	265,600,000							265,600,000
Proceeds from convertible senior notes in excess of initial liability component	79,400,000
Notes convertible into shares	7,439,000
Conversion rate of shares	21.5592
Conversion rate of principal amount	1,000
Price per share for conversion of debt	$46.38							$46.38
Number of trading days	20 days
Percentage of conversion price equal to or more than the last trading day	130.00%
Debt conversion basis amount	1,000
Number of consecutive trading days	30 days
Costs related equity component charged to additional paid-in capital	2,500,000							2,500,000
Costs related to debt component, amortized and recorded as additional interest expense	8,300,000							8,300,000
Converted note capped call transactions cap price	$62.44
Capped calls expenses, charged to additional paid-in capital	44,300,000
Convertible notes equity component carrying value	79,400,000							79,400,000					79,400,000
Total interest cost recognized during the period	21,700,000	20,700,000						7,300,000	7,000,000
Amortization of debt discount	13,400,000	12,300,000						4,500,000	4,200,000
Fair value of convertible debt	1,164,400,000							1,164,400,000
Convertible Senior Notes Due 2015 | Convertible Senior Notes
Debt Conversion [Line Items]
Effective interest rate on convertible note	8.35%	8.35%						8.35%	8.35%
Convertible Senior Notes Due 2015 | Maximum
Debt Conversion [Line Items]
Percentage of product of last reported sale price and conversion rate less than trading day period	98.00%
Convertible Senior Notes Due 2019
Debt Conversion [Line Items]
Convertible Senior Notes, par value	690,000,000							690,000,000		690,000,000			690,000,000
Net proceeds from offering										668,300,000
Convertible notes issuance date	16-Mar-12
Convertible senior notes, interest rate percentage	1.50%							1.50%
Convertible senior notes, frequency of periodic payment	Payable semiannually in arrears on March 15 and September 15 of each year
Convertible notes maturity date	15-Mar-19
Debt issuance costs	21,700,000
Effective interest rate on convertible note	5.50%							5.50%
Initial fair value of liability component due to convertible debt	529,300,000							529,300,000
Proceeds from convertible senior notes in excess of initial liability component	160,700,000
Notes convertible into shares	10,484,000
Conversion rate of shares	15.1947
Conversion rate of principal amount	1,000
Price per share for conversion of debt	$65.81							$65.81
Number of trading days	20 days
Percentage of conversion price equal to or more than the last trading day	130.00%
Debt conversion basis amount	1,000
Number of consecutive trading days	30 days
Costs related equity component charged to additional paid-in capital	5,100,000							5,100,000
Costs related to debt component, amortized and recorded as additional interest expense	16,600,000							16,600,000
Convertible notes equity component carrying value	160,700,000							160,700,000					160,700,000
Total interest cost recognized during the period	25,400,000	24,500,000						8,500,000	8,300,000
Amortization of debt discount	15,900,000	15,000,000						5,400,000	5,100,000
Fair value of convertible debt	1,675,000,000							1,675,000,000
Payments made for convertible bond hedge transactions	167,000,000
Amount received for warrants and credited to additional paid-in capital	99,000,000
Convertible Senior Notes Due 2019 | Convertible Senior Notes
Debt Conversion [Line Items]
Effective interest rate on convertible note	5.50%	5.50%						5.50%	5.50%
Convertible Senior Notes Due 2019 | Maximum
Debt Conversion [Line Items]
Percentage of product of last reported sale price and conversion rate less than trading day period	98.00%
Convertible Senior Notes Due 2019 | Privately Negotiated Warrant Transactions
Debt Conversion [Line Items]
Notes convertible into shares	10,484,000
Price per share for conversion of debt	$85.31							$85.31
2021 Notes
Debt Conversion [Line Items]
Convertible Senior Notes, par value											750,000,000
Net proceeds from offering											723,000,000
Convertible notes issuance date	27-Dec-13
Convertible senior notes, interest rate percentage	6.00%							6.00%
Convertible notes maturity date	15-Jan-21
Fair value of convertible debt	$813,800,000							$813,800,000
Issuance price percentage on fair value of notes											100.00%
Debt instrument redemption terms	At any time prior to January 15, 2017, the Company may, at its option, redeem some or all of the 2021 Notes at a redemption price of 100% of the principal amount thereof, plus a make-whole premium set forth in the indenture and accrued and unpaid interest, if any, to the redemption date.
Convertible senior notes, earliest redemption date that the company may redeem in whole or in part for Cash	15-Jan-17
Percentage of redemption price on principal amount	35.00%
Notes covenants description	The indenture contains covenants that restrict the ability of the Company and certain of its subsidiaries to, among other things (i) borrow money or issue preferred stock; (ii) pay dividends or make other payments or distributions on equity or purchase, redeem or otherwise acquire equity; (iii) make principal payments on, or purchase or redeem subordinated indebtedness prior to any scheduled principal payment or maturity; (iv) make certain investments; (v) create liens on their assets; (vi) sell their assets; (vii) enter into certain transactions with affiliates; (viii) engage in unrelated businesses and (ix) consolidate, merge or sell substantially all of the Company's assets.
Additional interest rate accrued on the notes	0.25%
Additional interest rate accruement period	90 days
Additional interest maximum rate accruement period	1.00%
2021 Notes | 12 month periods beginning on January 15, 2017
Debt Conversion [Line Items]
Percentage of redemption price on principal amount	104.50%
2021 Notes | 12 month periods beginning on January 15, 2018
Debt Conversion [Line Items]
Percentage of redemption price on principal amount	103.00%
2021 Notes | 12 month periods beginning on January 15, 2019
Debt Conversion [Line Items]
Percentage of redemption price on principal amount	101.50%
2021 Notes | 12 month periods beginning on January 15, 2020
Debt Conversion [Line Items]
Percentage of redemption price on principal amount	100.00%
2021 Notes | Prior to January 15, 2017
Debt Conversion [Line Items]
Percentage of redemption price on principal amount	106.00%

Notes_Summary_of_Information_o

Notes - Summary of Information on Convertible Senior Notes (Detail) (USD $)	Dec. 31, 2013	Sep. 30, 2014	Jun. 03, 2010	Mar. 16, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Net carrying amount	$882,050
Convertible Senior Notes Due 2015
Debt Instrument [Line Items]
Principal amount of the liability component	345,000	344,974	345,000
Unamortized discount	-26,356	-13,009
Net carrying amount	318,644	331,965
Convertible Senior Notes Due 2019
Debt Instrument [Line Items]
Principal amount of the liability component	690,000	690,000		690,000
Unamortized discount	-126,594	-110,702
Net carrying amount	563,406	579,298
Convertible Senior Notes
Debt Instrument [Line Items]
Principal amount of the liability component	1,035,000	1,034,974
Unamortized discount	-152,950	-123,711
Net carrying amount	$882,050	$911,263

Credit_Agreement_Additional_In

Credit Agreement - Additional Information (Detail) (USD $)	9 Months Ended	0 Months Ended
	Sep. 30, 2014	Jan. 02, 2014
Line of Credit Facility [Line Items]
Maturity date	2-Jan-20
Description of variable rate basis	(i) Adjusted LIBOR (as defined by the Credit Agreement), with a floor of 1.00%, plus a margin of 3.25% or (ii) the highest of (A) the Wall Street Journalbs published bU.S. Prime Lending Rate,b (B) the Federal Funds Effective Rate (as defined by the Credit Agreement) in effect on such day plus 0.50%, (C) one-month Adjusted LIBOR plus 1.00% per annum and (D) 2.00%, in each case plus a margin of 2.25%. If the ratio of the Companybs consolidated total debt to consolidated EBITDA, or the Total Leverage Ratio, is less than 3.75 to 1.00
Percentage of debt instrument, reduction rate	0.25%
Interest rate	2.00%
Leverage ratio	3.75%
Percentage of proceeds from asset sales	100.00%
Percentage of proceeds from debt financings	100.00%
Percentage of excess cash flow	50.00%
Term loan facility, description	The percentage of Excess Cash Flow that must be used to prepay the Term Loan B Facility decreases to 25% if the Total Leverage Ratio is less than 350 to 100 and to zero if the Total Leverage Ratio is less than 250 to 100
Prepayment of debt	$0
Adjusted Libor Plus [Member]
Line of Credit Facility [Line Items]
LIBOR floor rate	1.00%
Percentage of debt instrument, reduction rate	3.25%
Federal Funds Effective Rate [Member]
Line of Credit Facility [Line Items]
Percentage of debt instrument, reduction rate	0.50%
One Month Adjusted Libor Plus [Member]
Line of Credit Facility [Line Items]
LIBOR floor rate	1.00%
Percentage of debt instrument, reduction rate	2.25%
Term Loan B Facility [Member]
Line of Credit Facility [Line Items]
Percentage of amortization equal to principal amount	1.25%
Percentage of debt instrument, reduction rate	25.00%
Term Loan B Facility [Member] | Jefferies Finance LLC
Line of Credit Facility [Line Items]
Senior secured revolving credit facility		1,200,000,000
Length of credit agreement in years		6 years
Revolving credit facility
Line of Credit Facility [Line Items]
Percentage of debt instrument, reduction rate	25.00%
Revolving credit facility | Jefferies Finance LLC
Line of Credit Facility [Line Items]
Senior secured revolving credit facility		$150,000,000
Length of credit agreement in years		5 years

Research_and_Development_Addit

Research and Development - Additional Information (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Research and Development [Abstract]
Net liability related to on-going research and development activities	$15.10	$11.80

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Activity in Additional Paid-In-Capital (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Activity In Additional Paid-In-Capital [Line Items]
Beginning balance			$728,643
Ending balance	517,714		728,643
Additional Paid-in Capital [Member]
Activity In Additional Paid-In-Capital [Line Items]
Beginning balance	667,428	631,364
Issuance of common stock upon exercise of stock options	5,572	3,470
Payments related to net settlement of stock-based awards	-7,329	-4,037
Excess tax benefit from stock-based compensation	16,214	8,287
Compensation expense related to restricted stock awards	27,590	18,832
Reclassification of unamortized debt discount due on conversion of senior notes	-123,711
Ending balance	$585,764	$657,916

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	$11,154,000	$6,821,000	$27,591,000	$18,842,000
Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of forfeiture rate for estimation of restricted shares			9.40%
Allocated stock-based compensation expense	11,200,000	6,800,000	27,600,000	18,800,000
Unrecognized share-based compensation cost	114,300,000		114,300,000
Weighted-average period over which unrecognized share-based compensation will be recognized "in years"			3 years
Restricted Shares | Employees and Executives
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of restrictions lapse over four years			25.00%
Percentage of restrictions lapse over three years			33.00%
Restricted Shares | Board Members
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of restrictions lapse after one year			100.00%
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	0	0	0	0
Unrecognized share-based compensation cost	0		0
Issuance of common stock upon exercise of stock options (in shares)			299,816	200,000
Market value of outstanding stock	33,200,000	12,200,000	33,200,000	12,200,000
Total intrinsic value of options exercised	27,600,000	8,800,000	27,600,000	8,800,000
Cash received from stock options exercised			$5,600,000	$3,500,000

Stockholders_Equity_Aggregate_

Stockholders' Equity - Aggregate Stock Plan Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Shares Available For Grant, Beginning Balance	3,031,539
Total Shares Available For Grant, Granted	-963,071
Total Shares Available For Grant, Exercised	0
Total Shares Available For Grant, Vested	0
Total Shares Available For Grant, Additional shares authorized	1,500,000
Total Shares Available For Grant, Canceled	125,612
Total Shares Available For Grant, Ending Balance	3,694,080
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options, Number, Beginning Balance	498,493
Stock Options, Number, Granted	0
Stock Options, Number, Exercised	-299,816	-200,000
Stock Options, Number, Vested	0
Stock Options, Number, Canceled	-4,517
Stock Options, Number, Ending Balance	194,160
Stock Options, Weighted Average Price, Beginning Balance	$18.23
Stock Options, Weighted Average Price, Granted	$0
Stock Options, Weighted Average Price, Exercised	$18.58
Stock Options, Weighted Average Price, Vested	$0
Stock Options, Weighted Average Price, Canceled	$23.87
Stock Options, Weighted Average Price, Ending Balance	$17.56
Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Shares, Number Subject to Issuance, Beginning Balance	1,472,255
Restricted Shares, Number Subject to Issuance, Granted	963,071
Restricted Shares, Number Subject to Issuance, Exercised	0
Restricted Shares, Number Subject to Issuance, Vested	-480,537
Restricted Shares, Number Subject to Issuance, Canceled	-121,095
Restricted Shares, Number Subject to Issuance, Ending Balance	1,833,694
Restricted Shares, Weighted Average Price, Beginning Balance	$46.91
Restricted Shares, Weighted Average Price, Granted	$125.27
Restricted Shares, Weighted Average Price, Exercised	$0
Restricted Shares, Weighted Average Price, Vested	$37.56
Restricted Shares, Weighted Average Price, Canceled	$87.10
Restricted Shares, Weighted Average Price, Ending Balance	$87.86
Stock Options and Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options and Restricted Shares, Number, Beginning Balance	1,970,748
Stock Options and Restricted Shares, Number, Granted	963,071
Stock Options and Restricted Shares, Number, Exercised	-299,816
Stock Options and Restricted Shares, Number, Vested	-480,537
Stock Options and Restricted Shares, Number, Canceled	-125,612
Stock Options and Restricted Shares, Number, Ending Balance	2,027,854
Stock Options and Restricted Shares, Weighted Average Price, Beginning Balance	$39.66
Stock Options and Restricted Shares, Weighted Average Price, Granted	$125.27
Stock Options and Restricted Shares, Weighted Average Price, Exercised	$18.58
Stock Options and Restricted Shares, Weighted Average Price, Vested	$37.56
Stock Options and Restricted Shares, Weighted Average Price, Canceled	$84.83
Stock Options and Restricted Shares, Weighted Average Price, Ending Balance	$81.13

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Stock-Based Compensation Expense Incurred (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses	$11,154	$6,821	$27,591	$18,842
Research and Development Expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses	2,532	954	6,287	2,532
Selling, General and Administrative Expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expenses	$8,622	$5,867	$21,304	$16,310

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]
Effective tax rate	30.60%	23.10%	35.20%	30.60%
Statutory rate			35.00%

Net_Income_Loss_per_Share_Addi

Net Income (Loss) per Share - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Sep. 30, 2014
Earnings Per Share [Line Items]
Shares diluted due to conversion of notes, restricted stock or stock options	21,755	22,020
Convertible Senior Notes Due 2028
Earnings Per Share [Line Items]
Conversion price, per share					$9.25	$9.25
Shares included in diluted share calculation	6,486,000	6,486,000
Convertible Senior Notes Due 2028 | Repurchase of debt
Earnings Per Share [Line Items]
Shares included in diluted share calculation		1,351,000	2,730,000	2,405,000
Convertible Senior Notes Due 2015
Earnings Per Share [Line Items]
Conversion price, per share					$46.38	$46.38
Shares included in diluted share calculation	7,439,000	7,439,000			7,439,000
Convertible Senior Notes Due 2019
Earnings Per Share [Line Items]
Conversion price, per share					$65.81	$65.81
Shares included in diluted share calculation	10,484,000	10,484,000			10,484,000
Shares diluted due to conversion of notes, restricted stock or stock options					283,045	106,291

Net_Income_Loss_per_Share_Reco

Net Income (Loss) per Share - Reconciliation of Numerator and Denominator Used to Calculate Diluted Net Income (Loss) Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss)	($93,108)	$47,331	($127,267)	$90,772
Weighted average common shares, basic	63,687,000	61,763,000	63,482,000	61,416,000
Weighted average common shares, diluted	63,687,000	66,829,000	63,482,000	65,031,000
Restricted Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of restricted stock		675,000		552,000
Convertible Debt Securities
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of convertible debt		3,984,000		2,625,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of restricted stock		407,000		438,000

Segment_Reporting_Net_Product_

Segment Reporting - Net Product Revenues by Product Category (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]
Net product revenues	$341,547	$238,184	$1,120,066	$676,226
Xifaxan
Segment Reporting Information [Line Items]
Net product revenues	155,815	165,927	412,740	469,799
Inflammatory Bowel Disease - Apriso/Uceris/Giazo/Colazal [Member]
Segment Reporting Information [Line Items]
Net product revenues	73,126	38,321	220,199	101,927
Diabetes - Glumetza and Cycloset [Member]
Segment Reporting Information [Line Items]
Net product revenues	65,470		316,102
Purgatives - OsmoPrep/MoviPrep
Segment Reporting Information [Line Items]
Net product revenues	-1,263	19,232	15,404	54,108
Zegerid [Member]
Segment Reporting Information [Line Items]
Net product revenues	26,546		91,303
Other - Fenoglide/Anusol/Azasan/Diuril/Pepcid/Proctocort/Relistor/Deflux/Solesta/Fulyzaq/Metozolv [Member]
Segment Reporting Information [Line Items]
Net product revenues	$21,853	$14,704	$64,318	$50,392

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

In Millions, unless otherwise specified

Sep. 22, 2014

Nov. 12, 2013

5-May-11

Apr. 30, 2010

Oct. 03, 2014

Oct. 02, 2014

Sep. 30, 2012

Mar. 31, 2013

Feb. 18, 2014

Jan. 31, 2013

Sep. 07, 2014

Jul. 17, 2014

Sep. 30, 2014

Lawsuits

Patent

Patent

Patent

Patent

Product Liability Contingency [Line Items]

Minimum unspecified damages sought by plaintiff

$150

Number of lawsuits

11

Merger completion date

2-Jan-14

Number of invalid patents

5

Payment to escrow account

100

Subsequent Event | Cosmo Technologies Limited [Member]

Product Liability Contingency [Line Items]

Payment made by the company in termination of merger agreement

$25

$25

Invalidity For Asserted Claims [Member]

Product Liability Contingency [Line Items]

Number of invalid patents

3

Damage Claim [Member]

Product Liability Contingency [Line Items]

Number of invalid patents

2

Novel Litigation [Member]

Product Liability Contingency [Line Items]

Suit filing period

45 days

Period of stay for suit filed

30 months

Fenoglide Patent Litigation [Member]

Product Liability Contingency [Line Items]

Suit filing period

45 days

Period of stay for suit filed

30 months

Mylan Litigation [Member]

Product Liability Contingency [Line Items]

Suit filing period

45 days

Period of stay for suit filed

30 months

Lupin Litigation [Member]

Product Liability Contingency [Line Items]

Number of patents

5

Par Litigation [Member]

Product Liability Contingency [Line Items]

Suit filing period

45 days

Period of stay for suit filed

30 months

Delaware Court of Chancery [Member]

Product Liability Contingency [Line Items]

Number of lawsuits

9

California Superior Court [Member]

Product Liability Contingency [Line Items]

Number of lawsuits

1

U.S. District Court for the Southern District of California [Member]

Product Liability Contingency [Line Items]

Number of lawsuits

1

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (Subsequent Event, USD $)	0 Months Ended
In Millions, except Per Share data, unless otherwise specified	Oct. 03, 2014	Oct. 02, 2014	Feb. 22, 2015
Valeant Pharmaceuticals International Inc [Member]
Subsequent Event [Line Items]
Business acquisition purchase price per share			$158
Cosmo Technologies Limited [Member]
Subsequent Event [Line Items]
Payment made by the company in termination of merger agreement	$25	$25